wad基因缺陷与鼻窦细菌黏附的相关研究
|
摘要
本课题选肥大细胞基因缺陷鼠和同品系正常鼠作为研究对象,在变态反应性鼻炎模型建立细菌感染性鼻窦炎模型。借助三维测量法定量分析鼻窦粘膜的炎性细胞浸润、肥大细胞脱颗粒、致病菌与鼻窦粘膜的相互构筑关系等,同时进行鼻窦粘膜上皮线粒体、线粒体内自嗜体及上皮与致病菌的关系等超微结构分析。通过测定鼻窦粘膜表面短路电流、以及分析“辣根过氧化物酶”跨细胞转运的速率等,评估鼻窦粘膜的上皮屏障功能。借助微渗泵进行化学性干预。本研究旨在阐明:呼吸道变态反应性炎症的发病并非首先是Th1/Th2及相关的细胞因子失平衡所致,而可能首先是肥大细胞基因表达异常所致;由肥大细胞介导的鼻变态反应性炎症是诱发鼻窦炎的关键因素。研究分为四部分,主要结果和内容如下:
一、肥大细胞基因缺陷鼠急性细菌性鼻窦炎模型的构建
目的:探讨肥大细胞缺失c-kit基因突变纯合子鼠(简称WADm/m小鼠)和和其同源的c-kit基因突变杂合子鼠(简称WADm/+小鼠)细菌性鼻窦炎与变应性鼻炎的复合模型的感染过程及二者之间的差别。材料与方法健康清洁级Wadm/m小鼠(A、C、E、G)和Wadm/+小鼠(B、D、F、H)各40只,每组随机分为4组:A组、B组(卵清蛋白+生理盐水);C组、D组(卵清蛋白+肺炎链球菌);E组F组(PBS+肺炎链球菌);G组、H组(PBS+生理盐水),每组各10只。①实验第0～8天A、B、C和D组用10%卵清蛋白(ovalbumin)腹腔注射、第9～16天6%卵清蛋白鼻腔局部激发制成AR模型;其余四组用PBS替代。②在AR基础上于实验第12天C、D、E、F组鼻腔滴入肺炎链球菌ATCC 49619(1.2×109CFU/ml);A、B组和G、H组用生理盐水代替。细菌滴鼻后分别于接种2d (各2只)、5d (各4只)、l0d (各2只)、14d (各2只)处死动物,对照组于第5天处死.,处死前各组动物内眦静脉采血,收集鼻腔灌洗液,以间接酶联免疫吸附试验(ELISA)检测血清白细胞介素-5(IL-5,IL-13)水平;取鼻面骨,石蜡包埋,连续切片,HE染色和甲苯胺蓝染色,计算机辅助光学显微镜观察肥大细胞浸润情况,计算每平方毫米鼻窦黏膜中多形核中性粒细胞(,PMN)数目。处死前作鼻腔灌洗培养,头颅石蜡包埋,连续切片,HE染色,计算机辅助光镜观察,计算窦腔内中性粒细胞集落所占窦腔的百分率和每平方毫米窦腔粘膜中浸润的多形核白细胞数。结果:WADm/+组成功的诱导出过敏性鼻炎的模型,WADm/m经致敏后未出现典型的过敏性鼻炎的模型,接种后5天WADm/m、WADm/+感染组与复合模型组窦腔感染均达到高峰,窦腔中白细胞集落和粘膜中白细胞数均明显高于对照组(P<0.05),10天后WADm/m、WADm/+小鼠单纯感染组窦腔感染逐渐减轻,14d后基本控制,而变态反应和感染复合模型组小鼠感染持续存在,与单纯感染组比较差异有显著性(P<0.05 ), 14d后复合模型组鼻灌洗液中仍培养出肺炎链球菌。结论采用肺炎链球菌ATCC 49619鼻内接种法成功地诱导出WADm/+小鼠急性鼻窦炎的模型中,肺炎链球菌在鼻腔鼻窦内的感染可被完全、自主、快速控制,但肥大细胞基因缺陷鼠wadm/m的鼻窦炎的模型,以及建立的wads的变态反应与鼻窦炎复合模型由于在鼻过敏基础上诱发鼻窦炎导致症状持续存在,并有演变成慢性炎症的倾向,提示变态反应在鼻窦炎的发病机制中具有关键性作用,肥大细胞缺失鼠未能成功的建立变应性鼻炎的模型,证实了肥大细胞在速发和迟发的变态反应中具有重要作用。肥大细胞基因缺陷鼠可作为研究鼻腔学病理生理学的工具.由于肥大细胞基因缺陷具有很好的实验对照,故该鼠可以作为研究鼻腔疾病的免疫学,病理学和生理学理想的动物。
二、小鼠变应性鼻炎模型诱发细菌性鼻窦炎的研究
目的探讨变应性鼻炎(allergic rhinitis,AR)动物模型诱发细菌性鼻窦的方法。材料与方法健康清洁级C57BL6/J小鼠40只,随机分为4组:A组(卵清蛋白+肺炎链球菌);B组(卵清蛋白+生理盐水);C组(PBS+肺炎链球菌);D组(PBS+生理盐水),每组各10只。①实验第0～8天A组和B组用10%卵清蛋白(ovalbumin)腹腔注射、第9～16天6%卵清蛋白鼻腔局部激发制成AR模型;C组和D组用PBS替代。②在AR基础上于实验第12天A组和C组鼻腔滴入肺炎链球菌ATCC 49619 (1.2×109CFU/ml);B组和D组用生理盐水代替。细菌滴鼻后5d处死动物,处死前各组动物内眦静脉采血,以间接酶联免疫吸附试验(ELISA)检测血清白细胞介素-5(IL-5)水平;取鼻面骨,石蜡包埋,连续切片,HE染色和甲苯胺蓝染色,计算机辅助光学显微镜观察肥大细胞浸润情况,计算每平方毫米鼻窦黏膜中多形核中性粒细胞(polymorphonuclear neutrophils,PMN)和嗜酸粒细胞(eosinophil,Eos)数。结果A组和B组分别有9只和8只动物AR建模成功,鼻部症状、黏膜水肿和微血管扩张明显,C组症状轻微,D组无炎症表现。A组鼻窦黏膜PMN密度为(139.29±26.51)mm2,高于B组(70.67±16.74)mm2、C组(63.04±14.73)mm2和D组(40.24±14.05)mm2 (P均<0.01); A组和B组Eos密度和IL-5水平分别为(134.63±25.49)mm2、(48.21±13.94)pg/ml和(116.21±25.17)mm2、(40.83±7.78)pg/ml,均高于C组(16.71±2.68)mm2、(23.89±8.65)pg/ml(P均<0.05)和D组(13.39±4.95)mm2、(24.58±6.50)pg/ml(P均<0.05)。结论鼻-鼻窦局部变应性炎症反应增加了鼻窦黏膜的细菌感染;单纯的变应性炎症不会引起鼻窦感染,必须要有致病菌的存在。
三、肺表面活性物质相关蛋白D在鼻粘膜中的表达
肺表面活性物质相关蛋白D是胶原凝集素家族的承运在气道固有免疫的防御反应中具有重要作用,在肺的炎症性疾病和感染性疾病,如哮喘,肺的疾病,囊性纤维化,SPD的表达及功能的改变具有重要的意义,本研究旨在探讨SPD在鼻腔是否存在,通过探讨小鼠慢性鼻窦炎模型中鼻黏膜表面活性蛋白D(SP-D)表达、以探讨肺表面活性物质相关蛋白在慢性鼻窦炎发病中的作用机制。方法1、动物组:动物模型的制备健康清洁级Wadm/m小鼠(A、C、E、G)和Wadm/+小鼠(B、D、F、H)各40只,每组随机分为4组:A组、B组(卵清蛋白+生理盐水);C组、D组(卵清蛋白+肺炎链球菌);E组F组(PBS+肺炎链球菌);G组、H组(PBS+生理盐水),每组各10只。①实验第0～8天A、B、C和D组用10%卵清蛋白(ovalbumin)腹腔注射、第9～16天6%卵清蛋白鼻腔局部激发制成AR模型;其余四组用PBS替代。②在AR基础上于实验第12天C、D、E、F组鼻腔滴入肺炎链球菌ATCC49619 (1.2×109CFU/ml);A、B组和G、H组用生理盐水代替。用石蜡包埋鼻面骨,进行连续切片,应用免疫组化法检测鼻粘膜中表面活性蛋白D(SP-D)的表达。2:临床资料:回顾性分析了我科2005年-2007年住院接受接受鼻内镜手术的患者鼻组织标本随机选取慢性单纯性鼻炎10例,鼻息肉组10例,有明确的过敏性鼻炎合并鼻息肉10例组织标本进行SPD的染色分析。结果鼠及人的鼻粘膜标本提示SPD位于鼻粘膜的呼吸上皮的表面,另外在粘膜下浆液性腺体及导管上皮均存在表达,在增生纤维组织中可见散在阳性表达的炎症性细胞。
结论SPD在鼻粘膜存在表达,SPD可能参与鼻腔的固有免疫,外源性SP-D或人工重组的SP-D为治疗呼吸道的变应性疾病以及慢性炎症提供了新的思路,提高机体的固有免疫能力。
Mast cell deficient (Ws/Ws) rats and wild-type controls(+/+) rats will be chosen to studythe role of mast cells in the pathogenesis of nasal allergy. Ws/Ws rats will be sensitized toovalbumin followed by development of bacterial rhinosinusitis model through intranasalinoculation of selected bacteria. Inflammatory cell infiltration, mast cell degranulation as wellas bacterial-epithelial cell interactions will be quantitatively measured by a 3-D methods. At thesame time, mitochondria and autophagosomes in the nasal epithelia will be studied throughelectron microscopy. In addition, epithelial function will be measured by short-circuit current（Isc）on the nasal epithelia and and by transepithelial flux of horserdish peroxidase (HRP).Micro-osmotic pump will be used for chemical interference. We believe that allergicinflammatory mucosal disease in the upper respiratory tract may be initiated firstly and mainlyby mast cell, instead of the current conception of Th1/Th2 imbalance. Mast cell-dependentallergic reaction is a key factor for inducing the bacteria rhinosinusitis.
PartⅠ.Establishment of a mast cell-deficient mice Model of AcuteBacterial Rhinosinusitis by Allergic Rhinitis
Objective using to examine mast cell function in the nasal cavity，to explore the infectivecourse of bacterial rhinosinusitis based on allergic rhinitis in homozygous mutants Wadsm/m andheterozygote Wadsm/+（The mutation localized at W/c-kit）and the difference between themafter intranasal streptococcus pneumoniae inoculation. Methods Respectively 40 mice ofWadsm/m and Wadsm/+ were randomly divided averagely into 4 groups: A、B (OVA+NS) C、D(OVA+S.p.),E、F(PBS+ S.p.) and G、H(PBS+NS).①Group A、B、C and D were sensitizedto OVA（10％）by intraperitoneal injection on days 0 through 8, and exposed to OVA(6%)intranasally on days 9 through 16, as to induce allergic inflammation. PBS was used in group Cand D in the same way.②Subsequently, group C、D、E and F were inoculated S.p.（1.2×109CFU/ml）intranasally on day 12, and NS was used in other groups .After 2, 5, 10 and14 days, Blood was gathered from the orbital venous sinus after anesthesia. nasal lavage cuhureswere obtained and then the mice were killed. On the 6th day after inoculation, mice were killed.The heads were embedded with paraffin and serial sections were made and stained withhematoxlin-eosin and toluidine blue for histological analysis. The number of polymorphounclearneutrophils and eosinophils per square millimeter of sinus mucosa (PMN/mm2 and Eos/ mm2)were calculated by the use of computer aided microscope. ed. The heads were embedded with paraffin and serial sections were made for histological analysis. The percentage of sinus cavityoccupied by neutrophil cluster (% cluster) and the number of polymorphonuclear leukocytes persquare millimeter of sinus mucosa (PMN/ mm2) were calculated by the use of a computer aidedmicroscope in conjunction with a reconstruction and image analysis system. Results % Clusterand PMN/ mm2 in infected mice appeared to peak on five days，which were significantlyheavier than those in controls( P < 0. 05) . The infection in simple infection decreased by twoweeks. But in complex model of allergy and infection contrast to simple infection, the infectionin wadm/m had not been controlled and Streptococcus pneumoniae were still seen in the nasallavage cuhure by two weeks. Conclusion:AR models were successfully established from wadm/+mice . It was found that mast cell-deficient mice didn`t exhibited .Acute bacterial rhinosinusitisin wads are successfully induced by intranasal inoculation of streptococcus pneumoniae. Thisbacterial infection in the group of simple infection controlled completely and rapidly. Our datademonstrate that an ongoing local allergic response augments bacterial infection in these mice.Incontrast failed to control rhinosinusitis and had a tendency to chronic inflammation, suggestingthat mast cell was important for clearance of bacteria from rhinosinus and mast cell-deficientWads was a convenient tool for investigation of the pathogenesis of experimental rhinosinusitis.Mast cell-deficient mice has been developed for study of a variety of pathological,immunological, and physiological processes in the respiratory tract ,beacause this is a veryconvenient site for experimental manipulations.
PartⅡ.Establishment of a Mouse Model of Acute Bacterial Rhinosinusitis by AllergicRhinitis
Objective To develop a animal model of bacterial rhinosinusitis in mice with allergicrhinitis, and explore whether ongoing allergic rhinitis enhances the acute sinus infection andinflammation associated with Streptococcus pneumoniae. Methods 40 mice of C57BL6/J wererandomly divided averagely into 4 groups: A (OVA+S.p.), B(OVA+NS), C(PBS+ S.p.) andD(PBS+NS).①Group A and B were sensitized to OVA（10％）by intraperitoneal injectionon days 0 through 8, and exposed to OVA(6%) intranasally on days 9 through 16, as to induceallergic inflammation. PBS was used in group C and D in the same way.②Subsequently, groupA and C were inoculated S.p.（1.2×109CFU/ml）intranasally on day 12, and NS was used ingroup B and D. On the 6th day after inoculation, mice were killed. Blood was gathered from theorbital venous sinus after anesthesia. The heads were embedded with paraffin and serialsections were made and stained with hematoxlin-eosin and toluidine blue for histologicalanalysis. The number of polymorphounclear neutrophils and eosinophils per square millimeterof sinus mucosa (PMN/mm2 and Eos/ mm2) were calculated by the use of computer aided microscope. Results AR models were successfully established on 9 from group A and 8 fromgroup B. Histological examination of the sinus of group A and B revealed significant mucosaledema and dilated venules. The symptoms were mild in group C, and no symptom wasobserved in group D. PMN/mm2 in group A（139.29±26.51）mm2, were significantly heavierthan group B（70.67±16.74）mm2, C（63.04±14.73）mm2 and D（40.24±14.05）mm2 respectively（P＜0.01）; Eos/ mm2 and serous IL-5 level in group A（134.63±25.49）mm2,（48.21±13.94）pg/ml and B（116.21±25.17）mm2、（40.83±7.78）pg/ml, were higher than group C（16.71±2.68）mm2,（23.89±8.65）pg/ml（P＜0.05）and D（13.39±4.95）mm2,（24.58±6.50）pg/ml（P＜0.05）. Conclusion Our data demonstrate that an ongoing local allergic response augmentsbacterial infection in these mice, and allergic sensitization alone does not augment the sinusinfection without pathogenic bacterium.
Pa r tⅢ.Sur f a c t ant Pr o t e in D Expr e s s i on in Chr oni c Rhino s inus i t i s andImmune Responses
Objectives Surfactant-associated proteins (SP) D are in the family of collectin proteinsthat play an integral part in the innate defense system. SP-D expression and function are alteredin a variety of inflammatory and infectious diseases of the lungs, such as asthma, allergies, andcystic fibrosis. Our studies are the first to identify the presence of these proteins in the nasalcavity. The objective of this study was to immunolocalize SP-D in human sinonasaltissue.Methods Respectively 40 mice of Wadsm/m and Wadsm/+ were randomly dividedaveragely into 4 groups: A、B (OVA+NS) C、D(OVA+S.p.),E、F(PBS+ S.p.) and G、H(PBS+NS).①Group A、B、C and D were sensitized to OVA（10％）by intraperitoneal injection on days0 through 8, and exposed to OVA(6%) intranasally on days 9 through 16, as to induce allergicinflammation. PBS was used in group C and D in the same way.②Subsequently, group C、D、Eand F were inoculated S.p.（1.2×109CFU/ml）intranasally on day 12, and NS was used in othergroups . After 2, 5, 10 and 14 days, The heads were embedded with paraffin and serial sectionswere made for histological analysis. nasal mucosal biopsies were performed in patients withvarious forms of chronic hyperplastic rhinosinusitis with nasal polyposis and nondiseasedmucosa from patients undergoing (n = 10) Immunolocalization of surfactant proteins wasperformed with antibodies SP-D using immunoperoxidase staining technique. Isotype-negativecontrols were performed on all specimens.RESULTS: Analyses of mucosal biopsy specimensfrom nasal tissue reveals staining within respiratory and intermediate (metaplastic)-type surfaceepithelium. In addition, staining was intense in the submucosal ductal epithelium of theseromucinous glands. These properties appear to be consistent regardless of disease state andlocation within the sinuses.CONCLUSION: These are secreted proteins that are intricately involved in innate immunity in the lungs. Their secretion in the upper airway indicates thatfuture studies may allow manipulation of these proteins and development of novel treatments forsinonasal pathology.
一、肥大细胞基因缺陷鼠急性细菌性鼻窦炎模型的构建
目的:探讨肥大细胞缺失c-kit基因突变纯合子鼠(简称WADm/m小鼠)和和其同源的c-kit基因突变杂合子鼠(简称WADm/+小鼠)细菌性鼻窦炎与变应性鼻炎的复合模型的感染过程及二者之间的差别。材料与方法健康清洁级Wadm/m小鼠(A、C、E、G)和Wadm/+小鼠(B、D、F、H)各40只,每组随机分为4组:A组、B组(卵清蛋白+生理盐水);C组、D组(卵清蛋白+肺炎链球菌);E组F组(PBS+肺炎链球菌);G组、H组(PBS+生理盐水),每组各10只。①实验第0～8天A、B、C和D组用10%卵清蛋白(ovalbumin)腹腔注射、第9～16天6%卵清蛋白鼻腔局部激发制成AR模型;其余四组用PBS替代。②在AR基础上于实验第12天C、D、E、F组鼻腔滴入肺炎链球菌ATCC 49619(1.2×109CFU/ml);A、B组和G、H组用生理盐水代替。细菌滴鼻后分别于接种2d (各2只)、5d (各4只)、l0d (各2只)、14d (各2只)处死动物,对照组于第5天处死.,处死前各组动物内眦静脉采血,收集鼻腔灌洗液,以间接酶联免疫吸附试验(ELISA)检测血清白细胞介素-5(IL-5,IL-13)水平;取鼻面骨,石蜡包埋,连续切片,HE染色和甲苯胺蓝染色,计算机辅助光学显微镜观察肥大细胞浸润情况,计算每平方毫米鼻窦黏膜中多形核中性粒细胞(,PMN)数目。处死前作鼻腔灌洗培养,头颅石蜡包埋,连续切片,HE染色,计算机辅助光镜观察,计算窦腔内中性粒细胞集落所占窦腔的百分率和每平方毫米窦腔粘膜中浸润的多形核白细胞数。结果:WADm/+组成功的诱导出过敏性鼻炎的模型,WADm/m经致敏后未出现典型的过敏性鼻炎的模型,接种后5天WADm/m、WADm/+感染组与复合模型组窦腔感染均达到高峰,窦腔中白细胞集落和粘膜中白细胞数均明显高于对照组(P<0.05),10天后WADm/m、WADm/+小鼠单纯感染组窦腔感染逐渐减轻,14d后基本控制,而变态反应和感染复合模型组小鼠感染持续存在,与单纯感染组比较差异有显著性(P<0.05 ), 14d后复合模型组鼻灌洗液中仍培养出肺炎链球菌。结论采用肺炎链球菌ATCC 49619鼻内接种法成功地诱导出WADm/+小鼠急性鼻窦炎的模型中,肺炎链球菌在鼻腔鼻窦内的感染可被完全、自主、快速控制,但肥大细胞基因缺陷鼠wadm/m的鼻窦炎的模型,以及建立的wads的变态反应与鼻窦炎复合模型由于在鼻过敏基础上诱发鼻窦炎导致症状持续存在,并有演变成慢性炎症的倾向,提示变态反应在鼻窦炎的发病机制中具有关键性作用,肥大细胞缺失鼠未能成功的建立变应性鼻炎的模型,证实了肥大细胞在速发和迟发的变态反应中具有重要作用。肥大细胞基因缺陷鼠可作为研究鼻腔学病理生理学的工具.由于肥大细胞基因缺陷具有很好的实验对照,故该鼠可以作为研究鼻腔疾病的免疫学,病理学和生理学理想的动物。
二、小鼠变应性鼻炎模型诱发细菌性鼻窦炎的研究
目的探讨变应性鼻炎(allergic rhinitis,AR)动物模型诱发细菌性鼻窦的方法。材料与方法健康清洁级C57BL6/J小鼠40只,随机分为4组:A组(卵清蛋白+肺炎链球菌);B组(卵清蛋白+生理盐水);C组(PBS+肺炎链球菌);D组(PBS+生理盐水),每组各10只。①实验第0～8天A组和B组用10%卵清蛋白(ovalbumin)腹腔注射、第9～16天6%卵清蛋白鼻腔局部激发制成AR模型;C组和D组用PBS替代。②在AR基础上于实验第12天A组和C组鼻腔滴入肺炎链球菌ATCC 49619 (1.2×109CFU/ml);B组和D组用生理盐水代替。细菌滴鼻后5d处死动物,处死前各组动物内眦静脉采血,以间接酶联免疫吸附试验(ELISA)检测血清白细胞介素-5(IL-5)水平;取鼻面骨,石蜡包埋,连续切片,HE染色和甲苯胺蓝染色,计算机辅助光学显微镜观察肥大细胞浸润情况,计算每平方毫米鼻窦黏膜中多形核中性粒细胞(polymorphonuclear neutrophils,PMN)和嗜酸粒细胞(eosinophil,Eos)数。结果A组和B组分别有9只和8只动物AR建模成功,鼻部症状、黏膜水肿和微血管扩张明显,C组症状轻微,D组无炎症表现。A组鼻窦黏膜PMN密度为(139.29±26.51)mm2,高于B组(70.67±16.74)mm2、C组(63.04±14.73)mm2和D组(40.24±14.05)mm2 (P均<0.01); A组和B组Eos密度和IL-5水平分别为(134.63±25.49)mm2、(48.21±13.94)pg/ml和(116.21±25.17)mm2、(40.83±7.78)pg/ml,均高于C组(16.71±2.68)mm2、(23.89±8.65)pg/ml(P均<0.05)和D组(13.39±4.95)mm2、(24.58±6.50)pg/ml(P均<0.05)。结论鼻-鼻窦局部变应性炎症反应增加了鼻窦黏膜的细菌感染;单纯的变应性炎症不会引起鼻窦感染,必须要有致病菌的存在。
三、肺表面活性物质相关蛋白D在鼻粘膜中的表达
肺表面活性物质相关蛋白D是胶原凝集素家族的承运在气道固有免疫的防御反应中具有重要作用,在肺的炎症性疾病和感染性疾病,如哮喘,肺的疾病,囊性纤维化,SPD的表达及功能的改变具有重要的意义,本研究旨在探讨SPD在鼻腔是否存在,通过探讨小鼠慢性鼻窦炎模型中鼻黏膜表面活性蛋白D(SP-D)表达、以探讨肺表面活性物质相关蛋白在慢性鼻窦炎发病中的作用机制。方法1、动物组:动物模型的制备健康清洁级Wadm/m小鼠(A、C、E、G)和Wadm/+小鼠(B、D、F、H)各40只,每组随机分为4组:A组、B组(卵清蛋白+生理盐水);C组、D组(卵清蛋白+肺炎链球菌);E组F组(PBS+肺炎链球菌);G组、H组(PBS+生理盐水),每组各10只。①实验第0～8天A、B、C和D组用10%卵清蛋白(ovalbumin)腹腔注射、第9～16天6%卵清蛋白鼻腔局部激发制成AR模型;其余四组用PBS替代。②在AR基础上于实验第12天C、D、E、F组鼻腔滴入肺炎链球菌ATCC49619 (1.2×109CFU/ml);A、B组和G、H组用生理盐水代替。用石蜡包埋鼻面骨,进行连续切片,应用免疫组化法检测鼻粘膜中表面活性蛋白D(SP-D)的表达。2:临床资料:回顾性分析了我科2005年-2007年住院接受接受鼻内镜手术的患者鼻组织标本随机选取慢性单纯性鼻炎10例,鼻息肉组10例,有明确的过敏性鼻炎合并鼻息肉10例组织标本进行SPD的染色分析。结果鼠及人的鼻粘膜标本提示SPD位于鼻粘膜的呼吸上皮的表面,另外在粘膜下浆液性腺体及导管上皮均存在表达,在增生纤维组织中可见散在阳性表达的炎症性细胞。
结论SPD在鼻粘膜存在表达,SPD可能参与鼻腔的固有免疫,外源性SP-D或人工重组的SP-D为治疗呼吸道的变应性疾病以及慢性炎症提供了新的思路,提高机体的固有免疫能力。
Mast cell deficient (Ws/Ws) rats and wild-type controls(+/+) rats will be chosen to studythe role of mast cells in the pathogenesis of nasal allergy. Ws/Ws rats will be sensitized toovalbumin followed by development of bacterial rhinosinusitis model through intranasalinoculation of selected bacteria. Inflammatory cell infiltration, mast cell degranulation as wellas bacterial-epithelial cell interactions will be quantitatively measured by a 3-D methods. At thesame time, mitochondria and autophagosomes in the nasal epithelia will be studied throughelectron microscopy. In addition, epithelial function will be measured by short-circuit current（Isc）on the nasal epithelia and and by transepithelial flux of horserdish peroxidase (HRP).Micro-osmotic pump will be used for chemical interference. We believe that allergicinflammatory mucosal disease in the upper respiratory tract may be initiated firstly and mainlyby mast cell, instead of the current conception of Th1/Th2 imbalance. Mast cell-dependentallergic reaction is a key factor for inducing the bacteria rhinosinusitis.
PartⅠ.Establishment of a mast cell-deficient mice Model of AcuteBacterial Rhinosinusitis by Allergic Rhinitis
Objective using to examine mast cell function in the nasal cavity，to explore the infectivecourse of bacterial rhinosinusitis based on allergic rhinitis in homozygous mutants Wadsm/m andheterozygote Wadsm/+（The mutation localized at W/c-kit）and the difference between themafter intranasal streptococcus pneumoniae inoculation. Methods Respectively 40 mice ofWadsm/m and Wadsm/+ were randomly divided averagely into 4 groups: A、B (OVA+NS) C、D(OVA+S.p.),E、F(PBS+ S.p.) and G、H(PBS+NS).①Group A、B、C and D were sensitizedto OVA（10％）by intraperitoneal injection on days 0 through 8, and exposed to OVA(6%)intranasally on days 9 through 16, as to induce allergic inflammation. PBS was used in group Cand D in the same way.②Subsequently, group C、D、E and F were inoculated S.p.（1.2×109CFU/ml）intranasally on day 12, and NS was used in other groups .After 2, 5, 10 and14 days, Blood was gathered from the orbital venous sinus after anesthesia. nasal lavage cuhureswere obtained and then the mice were killed. On the 6th day after inoculation, mice were killed.The heads were embedded with paraffin and serial sections were made and stained withhematoxlin-eosin and toluidine blue for histological analysis. The number of polymorphounclearneutrophils and eosinophils per square millimeter of sinus mucosa (PMN/mm2 and Eos/ mm2)were calculated by the use of computer aided microscope. ed. The heads were embedded with paraffin and serial sections were made for histological analysis. The percentage of sinus cavityoccupied by neutrophil cluster (% cluster) and the number of polymorphonuclear leukocytes persquare millimeter of sinus mucosa (PMN/ mm2) were calculated by the use of a computer aidedmicroscope in conjunction with a reconstruction and image analysis system. Results % Clusterand PMN/ mm2 in infected mice appeared to peak on five days，which were significantlyheavier than those in controls( P < 0. 05) . The infection in simple infection decreased by twoweeks. But in complex model of allergy and infection contrast to simple infection, the infectionin wadm/m had not been controlled and Streptococcus pneumoniae were still seen in the nasallavage cuhure by two weeks. Conclusion:AR models were successfully established from wadm/+mice . It was found that mast cell-deficient mice didn`t exhibited .Acute bacterial rhinosinusitisin wads are successfully induced by intranasal inoculation of streptococcus pneumoniae. Thisbacterial infection in the group of simple infection controlled completely and rapidly. Our datademonstrate that an ongoing local allergic response augments bacterial infection in these mice.Incontrast failed to control rhinosinusitis and had a tendency to chronic inflammation, suggestingthat mast cell was important for clearance of bacteria from rhinosinus and mast cell-deficientWads was a convenient tool for investigation of the pathogenesis of experimental rhinosinusitis.Mast cell-deficient mice has been developed for study of a variety of pathological,immunological, and physiological processes in the respiratory tract ,beacause this is a veryconvenient site for experimental manipulations.
PartⅡ.Establishment of a Mouse Model of Acute Bacterial Rhinosinusitis by AllergicRhinitis
Objective To develop a animal model of bacterial rhinosinusitis in mice with allergicrhinitis, and explore whether ongoing allergic rhinitis enhances the acute sinus infection andinflammation associated with Streptococcus pneumoniae. Methods 40 mice of C57BL6/J wererandomly divided averagely into 4 groups: A (OVA+S.p.), B(OVA+NS), C(PBS+ S.p.) andD(PBS+NS).①Group A and B were sensitized to OVA（10％）by intraperitoneal injectionon days 0 through 8, and exposed to OVA(6%) intranasally on days 9 through 16, as to induceallergic inflammation. PBS was used in group C and D in the same way.②Subsequently, groupA and C were inoculated S.p.（1.2×109CFU/ml）intranasally on day 12, and NS was used ingroup B and D. On the 6th day after inoculation, mice were killed. Blood was gathered from theorbital venous sinus after anesthesia. The heads were embedded with paraffin and serialsections were made and stained with hematoxlin-eosin and toluidine blue for histologicalanalysis. The number of polymorphounclear neutrophils and eosinophils per square millimeterof sinus mucosa (PMN/mm2 and Eos/ mm2) were calculated by the use of computer aided microscope. Results AR models were successfully established on 9 from group A and 8 fromgroup B. Histological examination of the sinus of group A and B revealed significant mucosaledema and dilated venules. The symptoms were mild in group C, and no symptom wasobserved in group D. PMN/mm2 in group A（139.29±26.51）mm2, were significantly heavierthan group B（70.67±16.74）mm2, C（63.04±14.73）mm2 and D（40.24±14.05）mm2 respectively（P＜0.01）; Eos/ mm2 and serous IL-5 level in group A（134.63±25.49）mm2,（48.21±13.94）pg/ml and B（116.21±25.17）mm2、（40.83±7.78）pg/ml, were higher than group C（16.71±2.68）mm2,（23.89±8.65）pg/ml（P＜0.05）and D（13.39±4.95）mm2,（24.58±6.50）pg/ml（P＜0.05）. Conclusion Our data demonstrate that an ongoing local allergic response augmentsbacterial infection in these mice, and allergic sensitization alone does not augment the sinusinfection without pathogenic bacterium.
Pa r tⅢ.Sur f a c t ant Pr o t e in D Expr e s s i on in Chr oni c Rhino s inus i t i s andImmune Responses
Objectives Surfactant-associated proteins (SP) D are in the family of collectin proteinsthat play an integral part in the innate defense system. SP-D expression and function are alteredin a variety of inflammatory and infectious diseases of the lungs, such as asthma, allergies, andcystic fibrosis. Our studies are the first to identify the presence of these proteins in the nasalcavity. The objective of this study was to immunolocalize SP-D in human sinonasaltissue.Methods Respectively 40 mice of Wadsm/m and Wadsm/+ were randomly dividedaveragely into 4 groups: A、B (OVA+NS) C、D(OVA+S.p.),E、F(PBS+ S.p.) and G、H(PBS+NS).①Group A、B、C and D were sensitized to OVA（10％）by intraperitoneal injection on days0 through 8, and exposed to OVA(6%) intranasally on days 9 through 16, as to induce allergicinflammation. PBS was used in group C and D in the same way.②Subsequently, group C、D、Eand F were inoculated S.p.（1.2×109CFU/ml）intranasally on day 12, and NS was used in othergroups . After 2, 5, 10 and 14 days, The heads were embedded with paraffin and serial sectionswere made for histological analysis. nasal mucosal biopsies were performed in patients withvarious forms of chronic hyperplastic rhinosinusitis with nasal polyposis and nondiseasedmucosa from patients undergoing (n = 10) Immunolocalization of surfactant proteins wasperformed with antibodies SP-D using immunoperoxidase staining technique. Isotype-negativecontrols were performed on all specimens.RESULTS: Analyses of mucosal biopsy specimensfrom nasal tissue reveals staining within respiratory and intermediate (metaplastic)-type surfaceepithelium. In addition, staining was intense in the submucosal ductal epithelium of theseromucinous glands. These properties appear to be consistent regardless of disease state andlocation within the sinuses.CONCLUSION: These are secreted proteins that are intricately involved in innate immunity in the lungs. Their secretion in the upper airway indicates thatfuture studies may allow manipulation of these proteins and development of novel treatments forsinonasal pathology.
引文
[1] Giannoni CM,Stewart MG,Alford EL.Intracranial complications of sinusitis. ENTJ,2002,81:636-638,640-642,644.
[2] Kennedy DW.First-line management of sinusitis: a national problem? Surgicalupdate.Otolaryngol Head Neck Surg,1990,103:884-886.
[3] Osur SL.Viral respiratory infections in association with asthma and sinusitis: a review.AnnAllergyAsthma and Immunol,2002,89:553-560.
[4] Blair C,Nelson M,Thompson K,et al.Allergic inflammation enhances bacterial sinusitis inmice.J Allergy Clin Immunol,2001Sep,108(3):424-9.
[5] Bomer K,Brichta A,Baroody F,et al.A mouse model of acute bacterial rhinosinusitis.ArchOtolaryngol Head Neck Surg,1998,124:1227-1232.
[6] NAEPP report:overview of the pathogenesis of athsma.J Allergy Clin Immunol, 2002,S145-146.
[7] Bousquet J,Vignola AM,Campbell AM,et al.Pathophysiology of allergic rhinitis. Int ArchAllergyApplied Immunol,1996,110:207-218.
[8] Rudack C,Stoll W,Bachert C.Cytokines in nasal polyposis, acute and chronicsinusitis[J].Am J Rhinol,1998,12:383- 388
[9] Matthias FK,Peter O,Elisabeth P,et al.Nasal Interleukin- 5,Immunoglobulin E,EosinophilicCationic Protein,and Soluble Intercellular Adhesion Molecule -1 in ChronicSinusitis,Allergic Rhinitis,and Nasal Polyposis.Laryngoscope, 2000,110:1056-1062.
[10]Durham SR,Ying S,Varney VA,et al.Cytokine Messenger RNA expression for IL-3、IL-4、IL-5 and granulocyte/macrophage-colony-stimulating factor in the nasal mucosa after localallergen provocation:relationship to tissue eosinophilia. J Immunol, 1992,148:2390-2394.
[11]Schroder A J,Bloheta R A,Scholz M,et al.Effects of proinflammatory cytokines oncultivated primary human hepatocytes. Transplantation, 1995,59(7):1023.
[12]Santos J, Yang PC, S?derholm JD,et al. Role of mast cells in chronic stress induced colonicepithelial barrier dysfunction in the rat.Gut,2001,48:630- 636.
[13]Niwa Y,Kasugai T,Ohno K,et al.Anemia and mast cell depletion in mutant rats that arehomozygous at“white spotting (Ws)”locus,Blood 1991,78:1936–41.
[14]Horiguchi K,Komuro T.Ultrastructural characterization of interstitial cells of Cajal in therat small intestine using control andWs/Ws mutant rats. Cell Tissue Res,1998,293:277-84.
[15]Kennedy DW,Zinreich SJ,Rosenbaum AE,et al.Functional endoscopic sinus surgery:Theoryand diagnostic evaluation.Arch Otolaryngol,1985,111:576- 582.
[16]Berin MC,Kiliaan AJ,Yang PC,et al.The influence of mast cells on pathways oftransepithelial antigen transport in the rat intestine. J Immunol,1998, 161:2561-6.
[1] Askenase PW. Immunopat hology of parasitic diseases : involvement of basophils and mastcell s. Springer Semin Immunopat hol ,1980 ,2 (3) :417-442.
[2] Burnet FM. The probable relationship of some or all mast cells to t he T cell system. CellImmunol ,1977 ,30 (2) :358-360.
[3] Ruan HB,Zhang N,Gao X.Identification of a novel point mutation of mouse proto-oncogenec-kit through N-Ethyl-N-nitrosourea mutagenesis. Genetics,2005,169 (2):819-831 .
[4] Echtenacher B , Mannel DN , Hultner L. Critical protective role of mast cells in a model ofacute septic peritonitis [J ] . Nature , 1996 , 381(6657) : 75–77 .
[5] Kobayashi H , Ishizuka T, Okayama Y. Human mast cells and basophils as sources ofcytokines[J ] . Clin Exp Allergy , 2000 , 30 (9) : 1205 - 1212.
[6] Malaviya R , Ikeda T, Ross E , et al. Mast - cell modulation of neutrophil influx andbacterial clearance at sites of infection through TNF -α[J ] . Nature , 1996 , 381(6577) : 77 -80.
[7] Krishnaswamy G, Kelley J , Johnson D , et al. The human mast cell : functions in physiologyand disease [ J ] . Front Biosci , 2001 , 6 : D1109 - D1127. [7 ] Woolhiser MR , OkayamaY, Gilfillan AM, et al. IgG- de2 pendent activation of human mast cells following up -regula2 tion of Fc gamma RI by IFN - gamma [J ] . Eur J Immunol , 2001 , 31(11) : 3298 -3307.
[8]赵长青，李泽卿.译鼻窦疾病的诊断和治疗.北京：中国医药科技出版社,2006，107-115.
[9] Butter C, Lun A, Splettstoesser T,et al. Monclonal anti-interleukin-5 treatment suppresseseosinophil but not T-cell functions .Eur Resir J. 2003,21:799.
[10]安云芳,赵长青,王卫华,等.小鼠变应性鼻炎模型诱发急性细菌性鼻窦炎研究.中华耳鼻咽喉头颈外科杂志.2007,42:138-142.
[11]Windom HH, Togias A.Rhinitis and asthma:manifestation of one disease.Allergy ClinImmun Intemation，2001,13:154-161.
[12]商艳综述,李强审校.白介素13与支气管哮喘.国外医学·生理、病理科学与临床分册.2001,21:192-194
[13]Austen KF , Boyce JA. Mast cell lineage development and phenotype regulation. LeukRes ,2001 ,25 (7) :511-518.
[14]Williams CM , Galli SJ . The diverse potential effectors and immunoregulatory roles of mastcells in allergic disease. JAllergy Clin Immunol ,2000 ,105 (5) :847-859.
[15]Boyce JA. Mast cells : beyond IgE. J Allergy Clin Immunol ,2003 ,111 (1) :24-32.
[16]Rodewald HR ,Dessing M ,Dvorak ,AM , et al . Identification of acommitted precursor forthe mast cell lineage. Science ,1996 ,271(5250) :818-822.
[17]Rottem M ,Okada T ,Goff J P ,et al . Mast cells cultured f rom the peripheral blood ofnormaldonors and patient s with mastocytosis originate f rom a CD34 + / FcεR1-cellpopulation.Blood ,1994 ,84 (8) :2489-2496.
[18]Kirshenbaum AS ,Goff J P ,Semere T ,et al . Demonstration that human mast cells arise froma progenitor cell population that is CD34 ( + ) ,c-kit ( + ) ,and expresses amino peptidaseN(CD13) .Blood ,1999 ,94 (7) :2333-2342.
[19]Kitamura Y,Go S ,Hatanaka K. Decrease of mast cell s inW/Wv mice and t heir increase bybone marrow t ransplantation. Blood ,1978 ,52 (2) :447-452.
[20]Kitamura Y,Go S. Decreased production of mast cells in Sl/ Sld anemic mice.Blood 1979 ,53(3) :492-497.
[21]Metcalfe DD ,Baram D , Mekori YA. Mast cells. Physiol Rev ,1997 ,77 (4) :1033-1079.
[22]Haselden BM ,KayAB ,Larche M. Immunoglobin E-independent major histocompati- bilitycomplex-rest ricted T cell peptide epitope-induced late asthmatic reactions. J ExpMed ,1999 ,189(12) :1885-1894.
[23]Ali FR ,OldfieldWL , Higashi N ,et al . Late ast hmatic reactions induced by inhalation ofallergen-derived T cell peptides. Am J Respir Crit Care Med ,2004 ,169 (1) :20-26.
[24]Haselden BM , Larche M , Meng Q , et al . Late asthmatic reactions provoked by intradermalinjection of T-cell peptide epitopes are not associated wit h bronchial mucosal infiltrationofeosinophils or T( H) 2-type cells or with elevated concentrations of histamine oreicosanoids in bronchoalveolar fluid. J Allergy Clin Immunol ,2001 ,108 (3) 394-401.
[25]Hof stra CL ,Van Ark I ,Nijkamkp FP ,et al . Antigen-stimulated lung CD4 + cells prod- uceIL-5 ,while lymph node CD4 + cell sproduce Th2 cytokines concomitant with airw- ayeosinophilia and hyperresponsiveness. Inflamm Res ,1999 ,48 (11) :602-612.
[1]Osguthorpe JD.Adult rhinosinusitis:Diagnosis and management.Am Fam Physician,2001,63:69-76.
[2]Osur SL.Viral respiratory infections in association with asthma and sinusitis: a review. AnnAllergyAsthma and Immunol,2002,89:553-560.
[3]Togias A.Rhinitis and asthma:evidence for respiratory system integration.J Allergy ClinImmunol,2003, 11: 1171-1184.
[4]Mehle ME.Are nasal steroid safe? Current opinion in Otolaryngol Head and Neck surgery,2003,11:201-205.
[5]NAEPP report:overview of the pathogenesis of athsma.J Allergy Clin Immunol,2002,S145-146.
[6]Blair C,Nelson M,Thompson K,et al.Allergic inflammation enhances bacterial sinusitis inmice. J Allergy clin Immunol,2001,108:424-429.
[7]安云芳,赵长青,朱义庆,等.变应性鼻炎鼻黏膜P物质受体的研究.中华耳鼻咽喉科杂志,1998,33(3):139-141.
[8]Farrell BP.Endoscopic sinus surgery:sinonasal polyposis and allergy[J].Ear Nose ThrotJ,1993,72(2):544.
[9]Furukawa CT.The role of allergy in sinusitis in children.J Allergy clin Immunol,1992,90:515-517.
[10]Braunstahl GJ,Kleinjan A,Overbeek SE,et al.Segmental bronchial provocation induces nasalinflammation in allergic rhinitis patients.Am J Respir Crit Care Med,2000,161:2051- 2057.
[11]李宝实,冯文杰,胡雨田.鼻窦炎病因.见:卜国铉,主编.耳鼻咽喉科学鼻科学[M].第2版.上海:上海科学技术出版社.2000.312.
[12]Dasgupta MK,Costerton JW.Significance of biofilm-adherent bacterial microcolonies inTenckhoff catheters of CAPD patients.Blood Purif,1989,7(2-3):144-155.
[13]Bach JF.The effect of infectious on susceptibility to autoimmune and allergic diseaseas.NEngl J Med,2002,347: 911-920.
[14]Donnell MP.Renal tubulointerstitial fibrosis.New thoughts on its development and progression.Postgrad Med,2000,108:159.
[15]张罗,韩德民.IL-5在鼻息肉发病机制中的作用.国外医学耳鼻咽喉科学分册,2000,24(4):223.
[1] Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med 2000;343:338–344.
[2] Wright JR. Host defense functions of pulmonary surfactant. Biol Neonate 2004;85:326–332.
[3] Schaub B, Westlake RM, He H et al. Surfactant protein D deficiency influences allergicimmune responses. Clin Exp Allergy 2004;34:1819–1826.
[4] Madan T, Kishore U, Singh M et al. Surfactant proteins A and D protect mice againstpulmonary hypersensitivity induced by Aspergillus fumigatus antigens and allergens. J ClinInvest 2001;107:467–475.
[5] Hamilos DL. Chronic sinusitis. J Allergy Clin Immunol 2000; 106:213–227.
[6] Pant H, Kette FE, Smith WB et al. Fungal-specific humoral response in eosinophilic mucuschronic rhinosinusitis. Laryngosco- pe 2005;115:601–606.
[7] Stahlman MT, Gray ME, Hull WM, Whitsett JA. Immunolocalization of surfactant protein-D(SP-D) in human fetal, newborn, and adult tissues. J Histochem Cytochem2002; 50:651–660.
[8] Meltzer EO, Hamilos DL, Hadley JA et al. Rhinosinusitis: establishing definitions forclinical research and patient care. J Allergy Clin Immunol 2004;114:155–212.
[9] Collins M, Nair S, Smith W et al. Role of local immunoglobulin E production in thepathophysiology of noninvasive fungal sinusitis. Laryngoscope 2004;114:1242–1246.
[10]Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-timequantitative PCR and the 2(_Delta Delta C(T)) method. Methods 2001;25:402–408.
[11]Madsen J, Kliem A, Tornoe I et al. Localization of lung surfactant protein D on mucosalsurfaces in human tissues. J Immunol 2000;164:5866–5870.
[12]Grubor B, Gallup JM, Ramirez-Romero R et al. Surfactant protein D expression in normaland pneumonic ovine lung. Vet Immunol Immunopathol 2004;101:235–242.
[13]Madan T, Kishore U, Shah A et al. Lung surfactant proteins A and D can inhibit specific IgEbinding to the allergens of Aspergillus fumigatus and block allergen-inducedhistamine release from human basophils. Clin Exp Immunol 1997;110:241–249.
[14]Griese M. Pulmonary surfactant in health and human lung diseases : state of the art . EurRespir J ,1999 ,13 :1455-1476
[15]Hartl D , Grisese M. Surfactant protein D in hunman lung diseases. Euro J ClinicalInvestigation ,2006 ,36 :423-435.
[16]Crouch EC. Surfactant protein-D and pulmonary host defense. Respir Res ,2000 ,1 :93-108.
[17]Meschi J , Crouch EC , Skolnik P , et al . Surfactant protein D binds to humanimmunodeficiency virus ( HIV) envelope protein gp120 and inhibit s HIV replication. J GenVirol ,2005 ,86 :3097- 3107.
[18]Vuk-Pavlovic Z ,Mo EK, Icenhour CR ,et al . Surfactant protein D enhances pneumocystisinfection in immune suppressed mice. Am J Physiol Lung Cell MolPhysiol ,2006 ,290 :442-449.
[19]Madan T , Eggleton P , Kishore U , et al . Binding of surfactant proteins A and D toAspergillus fumigatus conidia enhances phagocytosis and killing by human neut rophils andalveolar macrophages. Infect Immun ,1997 ,65 :3171-3179.
[20]Fisher J H ,Larson J ,Cool C ,et al. Lymphocyte activation in the lungs of SP-D null mice.Am J Respir Cell Mol Biol ,2002,27 :24-33.
[21]Palaniyar N , Clark H , Nadesalingam J , et al . Innate immune collectin surfactant protein Denhances t he clearance of DNA by macrophages and minimizes anti-DNA antibodygeneration. J Immunol ,2005 ,174 :735—735
[22]Sano H ,Chiba H , Iwaki D , et al . Surfactant proteins A and D bind CD14 by differentmechanisms. J Biol Chem , 2000 , 275 :2244-2451.
[23]Gardai SJ ,Xiao YQ ,Dickinson M ,et al . By binding SIRPalpha or calreticulin/ CD91 , lungcollectins act as dual function surveillance molecules to suppress or enhanceinflammation. Cell ,2003 ,115 :13-23.
[24]Holmskov U , Lawson P , Teisner B , et al . Isolation and characterization of a new memberof t he scavenger receptor superfamily , glycoprotein-340 ( gp-340 ) , as a lungsurfactant protein D binding molecule. J Biol Chem , 1997 , 272: 13743- 13755.
[25]Prakobphol A , Xu F , Hoang VM , et al . Salivary agglutinin , which binds Streptococcusmutans and Helicobacter pylori , is t he lung scavenger receptor cysteine-rich protein gp-340.J Biol Chem ,2000 ,275 :39860-39866.
[26]Hart shorn KL ,White MR ,Mogues T , et al . Lung and salivary scavenger receptorglycoprotein-340 cont ribute to t he host defense against influenza A viruses. AmJ PhysiolLung Cell Mol Physiol ,2003 ,285 :1066-1076.
[27]Wang J Y,Kishore U ,Lim BL ,et al . Interaction of human lung surfactant proteins A and Dwit h mite ( Dermatophagoides pteronyssinus) allergens. Clin Exp Immunol , 1996 , 106 :367- 373.
[28]Inoue T , Mat suura E , Nagata A , et al . Enzyme-linked- immunosorbent-assay for humanpulmonary surfactant protein- D. J Immunol Met hods ,1994 ,173 :157-164.
[29]Koopmans J G, van der Zee J S , Krop EJM , et al . Serum surfactant protein D is elevated inallergic patient s. Clin Exp Allergy , 2004 ,34 :1827-1833.
[30]Pfister RH , Soll RF. New synt hetic surfactants : the next generation ?. BioNeonate ,2005 ,87 :338-344.
[31]Clark H , Reid K. The potential of recombinant surfactant protein D t herapy to reduce ininflammation in neonatal chronic lung disease , cystic fobrosis , and emphysema. Arch DisChild ,2003 ,88 :981-984.
[1] Lanza DC, Kennedy DW: Adult rhinosinusitis defined. Otolaryngol Head Neck Surg 1997,117:S1–S7.
[2] Christodoulopoulos P, Cameron L, Durham S, et al.: Molecular pathology of allergic diseaseII: upper airway disease. J Allergy Clin Immunol 2000, 105:211–223.
[3] Krouse JH: Computed tomography stage, allergy testing, and quality of life in patients withsinusitis. Otolaryngol Head Neck Surg 2000, 123:389–392.
[4] Stewart MG, Donovan DT, Parke RB Jr, et al.: Does the severity of sinus computedtomography findings predict outcome in chronic sinusitis? Otolaryngol Head Neck Surg2000, 123:81–84.
[5] Bhattacharyya N, Darshan VK, Fechner FP, et al.: Tissue eosinophilia in chronic sinusitis;quantification techniques. Arch Otolaryngol Head Neck Surg 2001, 127:1102–1105.
[6] Newman LJ, Platts-Mills TA, Phillips CD, et al.: Chronic sinusitis: relationship of computedtomographic findings to allergy, asthma, and eosinophilia. JAMA1994, 271:363–367.
[7] Elwany S, Bassyouni M, Morad F: Some risk factors for refractory sinusitis:an immunohistochemical and electron microscopic study. J Laryngol Otol2002, 116:112–115.
[8] Brinke AT, Grootendorst DC, Schmidt JT, et al.: Chronic sinusitis in severe asthma is relatedto sputum eosinophilia. J Allergy Clin Immunol 2002, 109:621–622
[9] Senior BA, Kennedy DW, Tanabodee J, et al.: Long-term impact of functional endoscopicsurgery on asthma. Otolaryngol Head Neck Surg 1999, 121:66–68.
[10]Riccio AM, Tosca MA, Cosentino C, et al.: Cytokine pattern in allergic and non-allergicchronic rhinosinusitis in asthmatic children. Clin Exp Allergy 2002, 32:422–426.
[11]Vinuya RZ: Upper airway disorders and asthma: a syndrome of airway inflammation. AnnAllergyAsthma Immunol 2002, 88:8–15.
[12]Dunlop G, Scadding GK, Lund VJ, et al.: The effect of endoscopic sinus surgery on asthma:management of patients with chronic rhinosinusitis, nasal polyposis, and asthma. Am JRhinol 1999, 13:261–265.
[13]Dhong H, Jung YS, Chung SK, et al.: Effect of endoscopic sinus surgery on asthmaticpatients with chronic rhinosinusitis. Otolaryngol Head Neck Surg 2001, 124:99–104.
[14]Corren J, Harris AG, Aaronson D, et al.: Efficacy and safety of loratadineplus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. J AllergyClin Immunol 1997, 100:781–788.
[15]Wilson AM, Orr LC, Sims EJ, et al.: Antiasthmatic effects of mediator blockade versustopical corticosteroids in allergic rhinitis and asthma. Am J Respir Crit Care Med 2000,162:1297–1301.
[16] Krouse JH, Krouse HJ: Patient use of traditional and complementary therapies in treatingrhinosinusitis before consulting an otolaryngologist. Laryngoscope 1999, 109:1223–1227.
[17]Lavigne F, Cameron L, Renzi PM, et al.: Intrasinus administration of topical budesonide toallergic patients with chronic rhinosinusitis following surgery. Laryngoscope 2002,112:858–864.
[18]Schurbert MS. A superantigen hypothesis for the pathogenesis of chronic hypertrophicrhinosinusitis，allergic fungal sinusitis,and related disorders. Ann AllergyAsthma Immunol，2001，87：181-188.
[19]Bachert C，Gevaert P，Holtappels G，et al. Total and specific IgE for staphylociccalenterotoxins in nasal polyps is related to local eosinophilic inflammation. J Allergy ClinImmunol，2001，107：607-614
[20]Berstein JM，Ballow M，Schlievert PM，et al. A superantigen hypothesis for the pathogenesisof chronic hyperplastic sinusitis with massive nasal polyposis，Am J Rhinology，2003，17：321-326
[21]Savolainen S. Allergy in patients with acute maxillary sinusitis. Allergy 1989; 44:116-122.
[22]Chen CF, Wu KG, Hsu MC, Tang RB. Prevalence and relationship between allergic diseaseand infectious diseases. J Microbiol Immunol Infect 2001; 34:57-62.
[23]Walker C, Williams H, Phelan J. Allergic rhinitis history as a predictor of other futuredisqualifying otorhinolaryngological defects. Aviat Space Environ Med 1998; 69:952-956.
[24]Holzmann D, Willi U, Nadal D. Allergic rhinitis as a risk factor for orbital complication ofacute rhinosinusitis in children. Am J Rhinol 2001; 15:387- 390.
[25]Parsons DS, Wald ER. Otitis media and sinusitis: similar disease. Otoloaryngol Clin NorthAm 1996; 29:11-19.
[26]Krause HF. Allergy and chronic rhinosinusitis. Otolaryngol Head Neck Surg 2003;128:14-16.
[27]Pelikan Z, Pelikan-Filipek M. Role of nasal allergic rhinitis in chronic maxillaryrhinosinusitis: diagnosis value of nasal challenge with allergen. J Allergy Clin Immunol1990; 86:484-491.
[28]Naclerio RM, deTineo ML, Baroody FM. Ragweed allergic rhinitis and the paranasalsinuses: a computed tomographic study. Arch Otolaryngol Head Neck Surg 1997;123:193-196.
[29]Berrettini S, Carabelli A, Sellari-Franceschini S, et al. Perennial allergic rhinitis and chronicsinusitis: correlation with rhinologic risk factors. Allergy 1999; 54:242-248.
[30]Adkins TN, Goodgold HM, Hendershott L, Slavin RG. Does inhaled pollen enter the sinuscavities? Ann AllergyAsthma Immunol 1998; 81:181-184.
[31]Gwaltney JM, Hendley JO, Phillips CD, et al. Nose blowing propels nasal fluid into theparanasal sinuses. Clin Infect Dis 2000; 30:387-391.
[32]Naclerio RM, Baroody FM, Nalini B, et al. A comparison of nasal clearance after treatmentof perennial allergic rhinitis with budesonide and mometasone. Otolaryngol Head Neck Surg2003; 128:220-227.
[33]Peebles RS, Hashimoto K, Graham BS. The complex relationship between respiratorysyntytial virus and allergy in lung disease. Viral Immunol 2003; 16:25-34.
[34]Sotir M, Yeatts K, Shy C. Presence of asthma risk factors and environmental exposuresrelated to upper respiratory infection-triggered wheezing in middle school-age children.Environ Health Perspect 2003; 111:657-662.
[35]Stephens R, Randolph DA, Huang G, et al. Antigen-nonspecific recruitment of Th2 cells tolung as a mechanism for viral infection-induced allergic asthma. J Immunol 2002;169:5458-5467.
[36]Harlin SL, Ansel DG, Lane SR, et al. A clinical and pathologic study of chronic sinusitis: therole of the eosinophil. J Allergy Clin Immunol 1988; 81:867-875.
[37]Suzuki M, Watanabe T, Suko T, Mogi G. Comparison of rhinosinusitis with and withoutallergic rhinitis: characteristics of paranasal sinus effusion and mucosa. Am J Otoloaryngol1999; 20:143-150.
[38]Elwany S, Bassyouni M, Morad F. Some risk factors for refractory chronic sinusitis: animmunohistochemical and electron microscopic study. J Laryngol Otol 2002; 116:112-115.
[39]Baroody FM, Anthony HC, Philip M, et al. Eosinophilia in chronic childhood sinusitis. ArchOtolaryngol Head Neck Surg 1995; 121:1396-1402.
[40]Hamilos DL, Leung DYM, Wood R, et al. Evidence for distinct cytokine expression inallergic versus non-allergic chronic sinusitis. J Allergy Clin Immunol 1995; 96:537-544.
[41]Hamilos DL, Leung DYM, Wood R, et al. Chronic hyperplastic sinusitis: association oftissue eosinophilia with mRNA expression of granulocyte-macrophage colony-stimulatingfactor and interleukin-3. J Allergy Clin Immunol 1993; 92:39-48.
[42]Hamilos DL, Leung DYM, Wood R, et al. Eosinophil infiltration in non-allergic chronichyperplastic sinusitis with nasal polyposis (CHS/NP) is associated with endothelialVCAM-1 upregulation and expression of TNFa. Am J Respir Cell Mol Biol 1996;15:443-450.
[43]Boyce JA. Mast cells: beyond IgE. J Allergy Clin Immunol 2003; 111:24-32.
[44]Driscoll PV, Naclerio RM, Baroody FM. CD4+ lymphocytes are increased in the sinusmucosa of children with chronic sinusitis. Arch Otolaryngol Head Neck Surg 1996;122:1071-1076.
[45]Blair C, Nelson M, Thomson K, et al. Allergic inflammation enhances bacterial sinusitis inmice. J Allergy Clin Immunol 2001; 108:424-429.
[46]Jyonouchi H, Sun S, Rimell F. Cytokine production by sinus lavage, bronchial lavage, andblood mononuclears in chronic rhinosinusitis with or without atopy. Arch Otolaryngol HeadNeck Surg 2000; 126:522-528.
[47]Riccio AM, Tosca MA, Cosentino C, et al. Cytokine pattern in allergic and non-allergicchronic rhinosinusitis in asthmatic children. Clin Exp Allergy 2002; 32:422-426.
[48]Ghamdi KA, Ghaffar O, Small P, et al. IL-4 and IL-13 expression in chronic sinusitis:relationship with cellular infiltrate and effect of topical corticosteroid treatment. JOtolaryngol 1997; 26:160-166.
[49]Wright ED, Frenkiel S, Al-Ghamdi K. Interleukin-4, interleukin-5, andgranulocyte-colony-stimulating factor receptor expression in chronic sinusitis and responseto topical steroids. Otolaryngol Head Neck Surg 1998; 118:490-495.
[50]Ferguson BJ, Johnson JT. Allergic rhinitis and rhinosinusitis: is there a connection betweenallergy and infection? Postgrad Med 1999; 105:55-58.
[51]Slavin RG, Zilliox AP, Samuels LD. Is there such an entity as allergic rhinosinusitis?[abstract]. J Allergy Clin Immunol 1988; 81:284.
[52]Braunstahl GJ, Kleinjan A, Overbeek SE, et al. Segmental bronchial provocation inducesnasal inflammation in allergic rhinitis patients. Am J Respir Crit Care Med 2000;161:2051-2057.
[53]Braunstahl GJ, Overbeek SE, Fokkens WJ, et al. Segmental bronchoprovo-cation in allergicrhinitis patients affects mast cell and basophil numbers in nasal and bronchial mucosa. Am JRespir Crit Care Med 2001; 164:858- 865.
[54]Baroody FM, Saengpanich S, deTineo M, et al. Nasal allergen challenge leads to bilateralmaxillary sinus eosinophil influx [abstract]. J Allergy Clin Immunol 2002; 109:S216.
[55]Schleimer RP, Togias AG. Introduction: systemic aspects of allergic disease. J Allergy ClinImmunol 2000; 106:S191.
[56]Feger TA, Rupp NT, Kuhn FA, et al. Local and systemic eosinophil activation in allergicfungal sinusitis. Ann AllergyAsthma Immunol 1997; 79:221-225.
[57]Stewart AE, Hunsaker DH. Fungus-specific IgG and IgE in allergic fungal rhinosinusitis.Otolaryngol Head Neck Surg 2002; 127:324-332.
[58]Khan DA, Cody T, George TJ, et al. Allergic fungal rhinosinusitis: an immunohistologicanalysis. J Allergy Clin Immunol 2000; 106:1096-1101.
[59]Ponikau J, Sherris DA, Kern EB, et al. The diagnosis and incidence of allergic fungalsinusitis. Mayo Clin Proc 1999; 74:877-884.
[60]Karp MW, Santeliz J, Karp CL. The germless theory of allergic disease: revisiting thehygiene hypothesis. Nat Rev Immunol 2002, 1:69-75.
[61]Allmers H, Schmengler J, Skudlik C. Primary prevention of natural rubber latex allergy inthe German health care system through education and intervention. J Allergy Clin Immunol2002; 88:16-22.
[62]Terreehorst I, Hak E, Oosting AJ, et al. Evaluation of impermeable covers for bedding inpatients with allergic rhinitis. N Engl J Med 2003; 349:237-246.
[63]Naclerio RM, Kagey-Sobotka A, Lichtenstein LM. Terfenadine, an H1 antihistamine,inhibits histamine release in vivo in the human. Am Rev Respir Dis 1990; 142:167-171.
[64]Walsh GM. The clinical relevance of the anti-inflammatory properties of antihistamines.Allergy 2000; 55:53-61.
[65]Braun JJ, Alabert JP, Michel FB, et al. Adjunct effect of loratadine in the treatment of acutesinusitis in patients with allergic rhinitis. Allergy 1997; 52:650-655.
[66]Borish L. The role of leukotrienes in upper and lower airway inflammation and theimplications for treatment. Ann AllergyAsthma Immunol 1996; 105:222- 225.
[67]Steinke JW, Bradley D, Arango P, et al. Cysteinyl leukotriene expression in chronichyperplastic sinusitis-nasal polyposis: importance to eosinophilia and asthma. J Allergy ClinImmunol 2003; 111:342-349.
[68]Bascom R, Wachs M, Naclerio RM, et al. Basophil influx occurs after nasal antigenchallenge: effects of topical corticosteroid pretreatment. J Allergy Clin Immunol 1988;81:580-589.
[69]Pipkorn U, Proud D, Lichtenstein LL, et al. Inhibition of mediator release in allergic rhinitisby pretreatment with topical glucocorticoids. N Engl J Med 1987; 316:1506-1510.
[70]Siegel SC, Katz R, Rachelefsky G, et al. Multicenter study of beclometha-sone dipropriate inadults with seasonal allergic rhinitis. J Allergy Clin Immunol 1982; 69:345-353.
[71]Johansen LV, Illum P, Kristensen S, et al. The effect of budesonide (Rhinocort) in thetreatment of small and medium-sized nasal polyps. Clin Otolaryngol 1993; 18:524-527.
[72]Ruhno J, Andersson B, Denberg J, et al. A double-blind comparison of intranasal budesonidewith placebo for nasal polyps. J Allergy Clin Immunol 1990; 86:946-953.
[73]Lildholt T, Rundcrantz H, Lindquist N. Efficacy of topical corticosteroid powder for nasalpolyps: a double-blind, placebo-controlled study of budesonide. Clin Otolaryngol 1995;20:26-30.
[74]Berggren F, Johansson L. Cost effectiveness of nasal budesonide versus surgical treatmentfor nasal polyps. Pharmacoeconomics 2003; 21:351-356.
[75]Barlan IB, Erkan E, Bakir M, et al. Intranasal budesonide spray as an adjunct to oralantibiotic therapy for acute sinusitis in children. Ann Allergy Asthma Immunol 1997;78:598-601.
[76]Dolor TJ, Witsell DV, Helkamp AS, et al. Comparison of cefuroxime with or withoutintranasal fluticasone for the treatment of rhinosinusitis. JAMA2001; 286:3097-3105.
[77]Meltzer EO, Orgel AH, Backhaus JW, et al. Intranasal flunisolide spray as an adjunct to oralantibiotic therapy for sinusitis. J Allergy Clin Immunol 1993; 92:812-823.
[78]Meltzer EO. Efficacy and patient satisfaction with cromolyn sodium nasal solution in thetreatment of seasonal allergic rhinitis: a placebo-controlled study. Clinical therapeutics 2002;24:942-952.
[79]Birchall MA, Henderson JC, Studham JM, et al. The effect of topical sodium cromoglycateon intranasal histamine challenge in allergic rhinitis. Clin Otolaryngol 1994; 19:521-525.
[80]Melen I, Friberg B, Andreasson L, et al. Effects of phenylpropanolamine on ostial and nasalpatency in patients treated for chronic maxillary sinusitis. Acta Otolaryngol 1986;101:494-500.
[81]Melen I, Andreasson L, Invarsson A, et al. Effects of phenylpropanolamine on ostial andnasal airway resistance in healthy individuals. Acta Otolaryngol 1986; 102:99-105.
[82]Bende M, Loth S. Vascular effects of topical oxymetazoline on human nasal mucosa. JLaryngol Otol 1986; 100:285-288.
[83]Wawrose SF, Tami TA, Amoils CP. The role of guaifenesin in the treatment of sinonasaldisease in patients infected with human immunodeficiency virus (HIV). Laryngoscope 1992;102:1225-1228.
[84]Durham SR, Walker SM, Samantha M, et al. Long-term clinical efficacy of grass-pollenimmunotherapy. N Engl J Med 1999; 341:468-475.
[85]Nishioka GJ, Cook PR, Davis WE, McKinsey JP. Immunotherapy in patients undergoingfunctional endoscopic sinus surgery. Otolaryngol Head Neck Surg 1994; 110:406-412.
[86]Mabry RL, Marple BF, Folker RJ, Mabry CS. Immunotherapy for allergic fungal sinusitis:three years' experience. Otolaryngol Head Neck Surg 1998; 119:648-651.
[87]Jiang RS, Hsu CY. Functional endoscopic sinus surgery in children and adults. Ann OtolRhinol Laryngol 2000; 109:1113-1136.
[88]Senior BA, Kennedy DW, Tanabodee J, et al. Long-term results of functional endoscopicsinus surgery. Laryngoscope 1998; 108:151-157.
[89]Lavigne F, Nguyen CT, Cameron L, et al. Prognosis and prediction of response to surgery inallergic patients with chronic sinusitis. J Allergy Clin Immunol 2000; 105:746-751.
[90]Palmer JN，Kennedy DW. Medical management in functional endoscopic sinus surgeryfailures. Curr Opin Otolaryngol Head Neck surg，2003，11：1，6-12.
[1] Richtsmeier W. J.,Top 10 Reasons for Endoscopic Maxillary Sinus Surgery Failure.Laryngoscope, 2001，111:1952–1956
[2] Tallon I: Axoneme structure and components. Hum Mol Genet, 2003；12 Review Issue 1，R27-R35
[3] Coste A, Girodon E, Louis S, et al., Atypical sinusitis in adults must lead to looking forcystic fibrosis and primary ciliary dyskinesia. Laryngoscope, 2004;114(5):837-843
[4]赵长青，李泽卿主译鼻窦疾病的诊断和治疗中国医药科技出版社，2006，P30-56，235-244
[5]赵长青.鼻内镜微创手术亟待规范.临床耳鼻咽喉头颈外科杂志，2007；21（5）：193-194
[6]周兵，韩德民，崔顺九，等.鼻内镜下鼻腔外侧壁切开上颌窦手术.中华耳鼻咽喉头颈外科杂志，2007；42（10）：743-748
[7] Tanna N, Edwards JD, Aghdam H, et al. Transnasal endoscopic medial maxillectomy as theinitial oncologic approach to sinonasal nesplasms-the anatomic basis.Arch Otolaryngol HeadNeck Surg. 2007;133(11):1139-1142
[8]于洪猛，赵长青主译.额窦，上海科技教育出版社，2007；P191-199
[2] Kennedy DW.First-line management of sinusitis: a national problem? Surgicalupdate.Otolaryngol Head Neck Surg,1990,103:884-886.
[3] Osur SL.Viral respiratory infections in association with asthma and sinusitis: a review.AnnAllergyAsthma and Immunol,2002,89:553-560.
[4] Blair C,Nelson M,Thompson K,et al.Allergic inflammation enhances bacterial sinusitis inmice.J Allergy Clin Immunol,2001Sep,108(3):424-9.
[5] Bomer K,Brichta A,Baroody F,et al.A mouse model of acute bacterial rhinosinusitis.ArchOtolaryngol Head Neck Surg,1998,124:1227-1232.
[6] NAEPP report:overview of the pathogenesis of athsma.J Allergy Clin Immunol, 2002,S145-146.
[7] Bousquet J,Vignola AM,Campbell AM,et al.Pathophysiology of allergic rhinitis. Int ArchAllergyApplied Immunol,1996,110:207-218.
[8] Rudack C,Stoll W,Bachert C.Cytokines in nasal polyposis, acute and chronicsinusitis[J].Am J Rhinol,1998,12:383- 388
[9] Matthias FK,Peter O,Elisabeth P,et al.Nasal Interleukin- 5,Immunoglobulin E,EosinophilicCationic Protein,and Soluble Intercellular Adhesion Molecule -1 in ChronicSinusitis,Allergic Rhinitis,and Nasal Polyposis.Laryngoscope, 2000,110:1056-1062.
[10]Durham SR,Ying S,Varney VA,et al.Cytokine Messenger RNA expression for IL-3、IL-4、IL-5 and granulocyte/macrophage-colony-stimulating factor in the nasal mucosa after localallergen provocation:relationship to tissue eosinophilia. J Immunol, 1992,148:2390-2394.
[11]Schroder A J,Bloheta R A,Scholz M,et al.Effects of proinflammatory cytokines oncultivated primary human hepatocytes. Transplantation, 1995,59(7):1023.
[12]Santos J, Yang PC, S?derholm JD,et al. Role of mast cells in chronic stress induced colonicepithelial barrier dysfunction in the rat.Gut,2001,48:630- 636.
[13]Niwa Y,Kasugai T,Ohno K,et al.Anemia and mast cell depletion in mutant rats that arehomozygous at“white spotting (Ws)”locus,Blood 1991,78:1936–41.
[14]Horiguchi K,Komuro T.Ultrastructural characterization of interstitial cells of Cajal in therat small intestine using control andWs/Ws mutant rats. Cell Tissue Res,1998,293:277-84.
[15]Kennedy DW,Zinreich SJ,Rosenbaum AE,et al.Functional endoscopic sinus surgery:Theoryand diagnostic evaluation.Arch Otolaryngol,1985,111:576- 582.
[16]Berin MC,Kiliaan AJ,Yang PC,et al.The influence of mast cells on pathways oftransepithelial antigen transport in the rat intestine. J Immunol,1998, 161:2561-6.
[1] Askenase PW. Immunopat hology of parasitic diseases : involvement of basophils and mastcell s. Springer Semin Immunopat hol ,1980 ,2 (3) :417-442.
[2] Burnet FM. The probable relationship of some or all mast cells to t he T cell system. CellImmunol ,1977 ,30 (2) :358-360.
[3] Ruan HB,Zhang N,Gao X.Identification of a novel point mutation of mouse proto-oncogenec-kit through N-Ethyl-N-nitrosourea mutagenesis. Genetics,2005,169 (2):819-831 .
[4] Echtenacher B , Mannel DN , Hultner L. Critical protective role of mast cells in a model ofacute septic peritonitis [J ] . Nature , 1996 , 381(6657) : 75–77 .
[5] Kobayashi H , Ishizuka T, Okayama Y. Human mast cells and basophils as sources ofcytokines[J ] . Clin Exp Allergy , 2000 , 30 (9) : 1205 - 1212.
[6] Malaviya R , Ikeda T, Ross E , et al. Mast - cell modulation of neutrophil influx andbacterial clearance at sites of infection through TNF -α[J ] . Nature , 1996 , 381(6577) : 77 -80.
[7] Krishnaswamy G, Kelley J , Johnson D , et al. The human mast cell : functions in physiologyand disease [ J ] . Front Biosci , 2001 , 6 : D1109 - D1127. [7 ] Woolhiser MR , OkayamaY, Gilfillan AM, et al. IgG- de2 pendent activation of human mast cells following up -regula2 tion of Fc gamma RI by IFN - gamma [J ] . Eur J Immunol , 2001 , 31(11) : 3298 -3307.
[8]赵长青，李泽卿.译鼻窦疾病的诊断和治疗.北京：中国医药科技出版社,2006，107-115.
[9] Butter C, Lun A, Splettstoesser T,et al. Monclonal anti-interleukin-5 treatment suppresseseosinophil but not T-cell functions .Eur Resir J. 2003,21:799.
[10]安云芳,赵长青,王卫华,等.小鼠变应性鼻炎模型诱发急性细菌性鼻窦炎研究.中华耳鼻咽喉头颈外科杂志.2007,42:138-142.
[11]Windom HH, Togias A.Rhinitis and asthma:manifestation of one disease.Allergy ClinImmun Intemation，2001,13:154-161.
[12]商艳综述,李强审校.白介素13与支气管哮喘.国外医学·生理、病理科学与临床分册.2001,21:192-194
[13]Austen KF , Boyce JA. Mast cell lineage development and phenotype regulation. LeukRes ,2001 ,25 (7) :511-518.
[14]Williams CM , Galli SJ . The diverse potential effectors and immunoregulatory roles of mastcells in allergic disease. JAllergy Clin Immunol ,2000 ,105 (5) :847-859.
[15]Boyce JA. Mast cells : beyond IgE. J Allergy Clin Immunol ,2003 ,111 (1) :24-32.
[16]Rodewald HR ,Dessing M ,Dvorak ,AM , et al . Identification of acommitted precursor forthe mast cell lineage. Science ,1996 ,271(5250) :818-822.
[17]Rottem M ,Okada T ,Goff J P ,et al . Mast cells cultured f rom the peripheral blood ofnormaldonors and patient s with mastocytosis originate f rom a CD34 + / FcεR1-cellpopulation.Blood ,1994 ,84 (8) :2489-2496.
[18]Kirshenbaum AS ,Goff J P ,Semere T ,et al . Demonstration that human mast cells arise froma progenitor cell population that is CD34 ( + ) ,c-kit ( + ) ,and expresses amino peptidaseN(CD13) .Blood ,1999 ,94 (7) :2333-2342.
[19]Kitamura Y,Go S ,Hatanaka K. Decrease of mast cell s inW/Wv mice and t heir increase bybone marrow t ransplantation. Blood ,1978 ,52 (2) :447-452.
[20]Kitamura Y,Go S. Decreased production of mast cells in Sl/ Sld anemic mice.Blood 1979 ,53(3) :492-497.
[21]Metcalfe DD ,Baram D , Mekori YA. Mast cells. Physiol Rev ,1997 ,77 (4) :1033-1079.
[22]Haselden BM ,KayAB ,Larche M. Immunoglobin E-independent major histocompati- bilitycomplex-rest ricted T cell peptide epitope-induced late asthmatic reactions. J ExpMed ,1999 ,189(12) :1885-1894.
[23]Ali FR ,OldfieldWL , Higashi N ,et al . Late ast hmatic reactions induced by inhalation ofallergen-derived T cell peptides. Am J Respir Crit Care Med ,2004 ,169 (1) :20-26.
[24]Haselden BM , Larche M , Meng Q , et al . Late asthmatic reactions provoked by intradermalinjection of T-cell peptide epitopes are not associated wit h bronchial mucosal infiltrationofeosinophils or T( H) 2-type cells or with elevated concentrations of histamine oreicosanoids in bronchoalveolar fluid. J Allergy Clin Immunol ,2001 ,108 (3) 394-401.
[25]Hof stra CL ,Van Ark I ,Nijkamkp FP ,et al . Antigen-stimulated lung CD4 + cells prod- uceIL-5 ,while lymph node CD4 + cell sproduce Th2 cytokines concomitant with airw- ayeosinophilia and hyperresponsiveness. Inflamm Res ,1999 ,48 (11) :602-612.
[1]Osguthorpe JD.Adult rhinosinusitis:Diagnosis and management.Am Fam Physician,2001,63:69-76.
[2]Osur SL.Viral respiratory infections in association with asthma and sinusitis: a review. AnnAllergyAsthma and Immunol,2002,89:553-560.
[3]Togias A.Rhinitis and asthma:evidence for respiratory system integration.J Allergy ClinImmunol,2003, 11: 1171-1184.
[4]Mehle ME.Are nasal steroid safe? Current opinion in Otolaryngol Head and Neck surgery,2003,11:201-205.
[5]NAEPP report:overview of the pathogenesis of athsma.J Allergy Clin Immunol,2002,S145-146.
[6]Blair C,Nelson M,Thompson K,et al.Allergic inflammation enhances bacterial sinusitis inmice. J Allergy clin Immunol,2001,108:424-429.
[7]安云芳,赵长青,朱义庆,等.变应性鼻炎鼻黏膜P物质受体的研究.中华耳鼻咽喉科杂志,1998,33(3):139-141.
[8]Farrell BP.Endoscopic sinus surgery:sinonasal polyposis and allergy[J].Ear Nose ThrotJ,1993,72(2):544.
[9]Furukawa CT.The role of allergy in sinusitis in children.J Allergy clin Immunol,1992,90:515-517.
[10]Braunstahl GJ,Kleinjan A,Overbeek SE,et al.Segmental bronchial provocation induces nasalinflammation in allergic rhinitis patients.Am J Respir Crit Care Med,2000,161:2051- 2057.
[11]李宝实,冯文杰,胡雨田.鼻窦炎病因.见:卜国铉,主编.耳鼻咽喉科学鼻科学[M].第2版.上海:上海科学技术出版社.2000.312.
[12]Dasgupta MK,Costerton JW.Significance of biofilm-adherent bacterial microcolonies inTenckhoff catheters of CAPD patients.Blood Purif,1989,7(2-3):144-155.
[13]Bach JF.The effect of infectious on susceptibility to autoimmune and allergic diseaseas.NEngl J Med,2002,347: 911-920.
[14]Donnell MP.Renal tubulointerstitial fibrosis.New thoughts on its development and progression.Postgrad Med,2000,108:159.
[15]张罗,韩德民.IL-5在鼻息肉发病机制中的作用.国外医学耳鼻咽喉科学分册,2000,24(4):223.
[1] Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med 2000;343:338–344.
[2] Wright JR. Host defense functions of pulmonary surfactant. Biol Neonate 2004;85:326–332.
[3] Schaub B, Westlake RM, He H et al. Surfactant protein D deficiency influences allergicimmune responses. Clin Exp Allergy 2004;34:1819–1826.
[4] Madan T, Kishore U, Singh M et al. Surfactant proteins A and D protect mice againstpulmonary hypersensitivity induced by Aspergillus fumigatus antigens and allergens. J ClinInvest 2001;107:467–475.
[5] Hamilos DL. Chronic sinusitis. J Allergy Clin Immunol 2000; 106:213–227.
[6] Pant H, Kette FE, Smith WB et al. Fungal-specific humoral response in eosinophilic mucuschronic rhinosinusitis. Laryngosco- pe 2005;115:601–606.
[7] Stahlman MT, Gray ME, Hull WM, Whitsett JA. Immunolocalization of surfactant protein-D(SP-D) in human fetal, newborn, and adult tissues. J Histochem Cytochem2002; 50:651–660.
[8] Meltzer EO, Hamilos DL, Hadley JA et al. Rhinosinusitis: establishing definitions forclinical research and patient care. J Allergy Clin Immunol 2004;114:155–212.
[9] Collins M, Nair S, Smith W et al. Role of local immunoglobulin E production in thepathophysiology of noninvasive fungal sinusitis. Laryngoscope 2004;114:1242–1246.
[10]Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-timequantitative PCR and the 2(_Delta Delta C(T)) method. Methods 2001;25:402–408.
[11]Madsen J, Kliem A, Tornoe I et al. Localization of lung surfactant protein D on mucosalsurfaces in human tissues. J Immunol 2000;164:5866–5870.
[12]Grubor B, Gallup JM, Ramirez-Romero R et al. Surfactant protein D expression in normaland pneumonic ovine lung. Vet Immunol Immunopathol 2004;101:235–242.
[13]Madan T, Kishore U, Shah A et al. Lung surfactant proteins A and D can inhibit specific IgEbinding to the allergens of Aspergillus fumigatus and block allergen-inducedhistamine release from human basophils. Clin Exp Immunol 1997;110:241–249.
[14]Griese M. Pulmonary surfactant in health and human lung diseases : state of the art . EurRespir J ,1999 ,13 :1455-1476
[15]Hartl D , Grisese M. Surfactant protein D in hunman lung diseases. Euro J ClinicalInvestigation ,2006 ,36 :423-435.
[16]Crouch EC. Surfactant protein-D and pulmonary host defense. Respir Res ,2000 ,1 :93-108.
[17]Meschi J , Crouch EC , Skolnik P , et al . Surfactant protein D binds to humanimmunodeficiency virus ( HIV) envelope protein gp120 and inhibit s HIV replication. J GenVirol ,2005 ,86 :3097- 3107.
[18]Vuk-Pavlovic Z ,Mo EK, Icenhour CR ,et al . Surfactant protein D enhances pneumocystisinfection in immune suppressed mice. Am J Physiol Lung Cell MolPhysiol ,2006 ,290 :442-449.
[19]Madan T , Eggleton P , Kishore U , et al . Binding of surfactant proteins A and D toAspergillus fumigatus conidia enhances phagocytosis and killing by human neut rophils andalveolar macrophages. Infect Immun ,1997 ,65 :3171-3179.
[20]Fisher J H ,Larson J ,Cool C ,et al. Lymphocyte activation in the lungs of SP-D null mice.Am J Respir Cell Mol Biol ,2002,27 :24-33.
[21]Palaniyar N , Clark H , Nadesalingam J , et al . Innate immune collectin surfactant protein Denhances t he clearance of DNA by macrophages and minimizes anti-DNA antibodygeneration. J Immunol ,2005 ,174 :735—735
[22]Sano H ,Chiba H , Iwaki D , et al . Surfactant proteins A and D bind CD14 by differentmechanisms. J Biol Chem , 2000 , 275 :2244-2451.
[23]Gardai SJ ,Xiao YQ ,Dickinson M ,et al . By binding SIRPalpha or calreticulin/ CD91 , lungcollectins act as dual function surveillance molecules to suppress or enhanceinflammation. Cell ,2003 ,115 :13-23.
[24]Holmskov U , Lawson P , Teisner B , et al . Isolation and characterization of a new memberof t he scavenger receptor superfamily , glycoprotein-340 ( gp-340 ) , as a lungsurfactant protein D binding molecule. J Biol Chem , 1997 , 272: 13743- 13755.
[25]Prakobphol A , Xu F , Hoang VM , et al . Salivary agglutinin , which binds Streptococcusmutans and Helicobacter pylori , is t he lung scavenger receptor cysteine-rich protein gp-340.J Biol Chem ,2000 ,275 :39860-39866.
[26]Hart shorn KL ,White MR ,Mogues T , et al . Lung and salivary scavenger receptorglycoprotein-340 cont ribute to t he host defense against influenza A viruses. AmJ PhysiolLung Cell Mol Physiol ,2003 ,285 :1066-1076.
[27]Wang J Y,Kishore U ,Lim BL ,et al . Interaction of human lung surfactant proteins A and Dwit h mite ( Dermatophagoides pteronyssinus) allergens. Clin Exp Immunol , 1996 , 106 :367- 373.
[28]Inoue T , Mat suura E , Nagata A , et al . Enzyme-linked- immunosorbent-assay for humanpulmonary surfactant protein- D. J Immunol Met hods ,1994 ,173 :157-164.
[29]Koopmans J G, van der Zee J S , Krop EJM , et al . Serum surfactant protein D is elevated inallergic patient s. Clin Exp Allergy , 2004 ,34 :1827-1833.
[30]Pfister RH , Soll RF. New synt hetic surfactants : the next generation ?. BioNeonate ,2005 ,87 :338-344.
[31]Clark H , Reid K. The potential of recombinant surfactant protein D t herapy to reduce ininflammation in neonatal chronic lung disease , cystic fobrosis , and emphysema. Arch DisChild ,2003 ,88 :981-984.
[1] Lanza DC, Kennedy DW: Adult rhinosinusitis defined. Otolaryngol Head Neck Surg 1997,117:S1–S7.
[2] Christodoulopoulos P, Cameron L, Durham S, et al.: Molecular pathology of allergic diseaseII: upper airway disease. J Allergy Clin Immunol 2000, 105:211–223.
[3] Krouse JH: Computed tomography stage, allergy testing, and quality of life in patients withsinusitis. Otolaryngol Head Neck Surg 2000, 123:389–392.
[4] Stewart MG, Donovan DT, Parke RB Jr, et al.: Does the severity of sinus computedtomography findings predict outcome in chronic sinusitis? Otolaryngol Head Neck Surg2000, 123:81–84.
[5] Bhattacharyya N, Darshan VK, Fechner FP, et al.: Tissue eosinophilia in chronic sinusitis;quantification techniques. Arch Otolaryngol Head Neck Surg 2001, 127:1102–1105.
[6] Newman LJ, Platts-Mills TA, Phillips CD, et al.: Chronic sinusitis: relationship of computedtomographic findings to allergy, asthma, and eosinophilia. JAMA1994, 271:363–367.
[7] Elwany S, Bassyouni M, Morad F: Some risk factors for refractory sinusitis:an immunohistochemical and electron microscopic study. J Laryngol Otol2002, 116:112–115.
[8] Brinke AT, Grootendorst DC, Schmidt JT, et al.: Chronic sinusitis in severe asthma is relatedto sputum eosinophilia. J Allergy Clin Immunol 2002, 109:621–622
[9] Senior BA, Kennedy DW, Tanabodee J, et al.: Long-term impact of functional endoscopicsurgery on asthma. Otolaryngol Head Neck Surg 1999, 121:66–68.
[10]Riccio AM, Tosca MA, Cosentino C, et al.: Cytokine pattern in allergic and non-allergicchronic rhinosinusitis in asthmatic children. Clin Exp Allergy 2002, 32:422–426.
[11]Vinuya RZ: Upper airway disorders and asthma: a syndrome of airway inflammation. AnnAllergyAsthma Immunol 2002, 88:8–15.
[12]Dunlop G, Scadding GK, Lund VJ, et al.: The effect of endoscopic sinus surgery on asthma:management of patients with chronic rhinosinusitis, nasal polyposis, and asthma. Am JRhinol 1999, 13:261–265.
[13]Dhong H, Jung YS, Chung SK, et al.: Effect of endoscopic sinus surgery on asthmaticpatients with chronic rhinosinusitis. Otolaryngol Head Neck Surg 2001, 124:99–104.
[14]Corren J, Harris AG, Aaronson D, et al.: Efficacy and safety of loratadineplus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. J AllergyClin Immunol 1997, 100:781–788.
[15]Wilson AM, Orr LC, Sims EJ, et al.: Antiasthmatic effects of mediator blockade versustopical corticosteroids in allergic rhinitis and asthma. Am J Respir Crit Care Med 2000,162:1297–1301.
[16] Krouse JH, Krouse HJ: Patient use of traditional and complementary therapies in treatingrhinosinusitis before consulting an otolaryngologist. Laryngoscope 1999, 109:1223–1227.
[17]Lavigne F, Cameron L, Renzi PM, et al.: Intrasinus administration of topical budesonide toallergic patients with chronic rhinosinusitis following surgery. Laryngoscope 2002,112:858–864.
[18]Schurbert MS. A superantigen hypothesis for the pathogenesis of chronic hypertrophicrhinosinusitis，allergic fungal sinusitis,and related disorders. Ann AllergyAsthma Immunol，2001，87：181-188.
[19]Bachert C，Gevaert P，Holtappels G，et al. Total and specific IgE for staphylociccalenterotoxins in nasal polyps is related to local eosinophilic inflammation. J Allergy ClinImmunol，2001，107：607-614
[20]Berstein JM，Ballow M，Schlievert PM，et al. A superantigen hypothesis for the pathogenesisof chronic hyperplastic sinusitis with massive nasal polyposis，Am J Rhinology，2003，17：321-326
[21]Savolainen S. Allergy in patients with acute maxillary sinusitis. Allergy 1989; 44:116-122.
[22]Chen CF, Wu KG, Hsu MC, Tang RB. Prevalence and relationship between allergic diseaseand infectious diseases. J Microbiol Immunol Infect 2001; 34:57-62.
[23]Walker C, Williams H, Phelan J. Allergic rhinitis history as a predictor of other futuredisqualifying otorhinolaryngological defects. Aviat Space Environ Med 1998; 69:952-956.
[24]Holzmann D, Willi U, Nadal D. Allergic rhinitis as a risk factor for orbital complication ofacute rhinosinusitis in children. Am J Rhinol 2001; 15:387- 390.
[25]Parsons DS, Wald ER. Otitis media and sinusitis: similar disease. Otoloaryngol Clin NorthAm 1996; 29:11-19.
[26]Krause HF. Allergy and chronic rhinosinusitis. Otolaryngol Head Neck Surg 2003;128:14-16.
[27]Pelikan Z, Pelikan-Filipek M. Role of nasal allergic rhinitis in chronic maxillaryrhinosinusitis: diagnosis value of nasal challenge with allergen. J Allergy Clin Immunol1990; 86:484-491.
[28]Naclerio RM, deTineo ML, Baroody FM. Ragweed allergic rhinitis and the paranasalsinuses: a computed tomographic study. Arch Otolaryngol Head Neck Surg 1997;123:193-196.
[29]Berrettini S, Carabelli A, Sellari-Franceschini S, et al. Perennial allergic rhinitis and chronicsinusitis: correlation with rhinologic risk factors. Allergy 1999; 54:242-248.
[30]Adkins TN, Goodgold HM, Hendershott L, Slavin RG. Does inhaled pollen enter the sinuscavities? Ann AllergyAsthma Immunol 1998; 81:181-184.
[31]Gwaltney JM, Hendley JO, Phillips CD, et al. Nose blowing propels nasal fluid into theparanasal sinuses. Clin Infect Dis 2000; 30:387-391.
[32]Naclerio RM, Baroody FM, Nalini B, et al. A comparison of nasal clearance after treatmentof perennial allergic rhinitis with budesonide and mometasone. Otolaryngol Head Neck Surg2003; 128:220-227.
[33]Peebles RS, Hashimoto K, Graham BS. The complex relationship between respiratorysyntytial virus and allergy in lung disease. Viral Immunol 2003; 16:25-34.
[34]Sotir M, Yeatts K, Shy C. Presence of asthma risk factors and environmental exposuresrelated to upper respiratory infection-triggered wheezing in middle school-age children.Environ Health Perspect 2003; 111:657-662.
[35]Stephens R, Randolph DA, Huang G, et al. Antigen-nonspecific recruitment of Th2 cells tolung as a mechanism for viral infection-induced allergic asthma. J Immunol 2002;169:5458-5467.
[36]Harlin SL, Ansel DG, Lane SR, et al. A clinical and pathologic study of chronic sinusitis: therole of the eosinophil. J Allergy Clin Immunol 1988; 81:867-875.
[37]Suzuki M, Watanabe T, Suko T, Mogi G. Comparison of rhinosinusitis with and withoutallergic rhinitis: characteristics of paranasal sinus effusion and mucosa. Am J Otoloaryngol1999; 20:143-150.
[38]Elwany S, Bassyouni M, Morad F. Some risk factors for refractory chronic sinusitis: animmunohistochemical and electron microscopic study. J Laryngol Otol 2002; 116:112-115.
[39]Baroody FM, Anthony HC, Philip M, et al. Eosinophilia in chronic childhood sinusitis. ArchOtolaryngol Head Neck Surg 1995; 121:1396-1402.
[40]Hamilos DL, Leung DYM, Wood R, et al. Evidence for distinct cytokine expression inallergic versus non-allergic chronic sinusitis. J Allergy Clin Immunol 1995; 96:537-544.
[41]Hamilos DL, Leung DYM, Wood R, et al. Chronic hyperplastic sinusitis: association oftissue eosinophilia with mRNA expression of granulocyte-macrophage colony-stimulatingfactor and interleukin-3. J Allergy Clin Immunol 1993; 92:39-48.
[42]Hamilos DL, Leung DYM, Wood R, et al. Eosinophil infiltration in non-allergic chronichyperplastic sinusitis with nasal polyposis (CHS/NP) is associated with endothelialVCAM-1 upregulation and expression of TNFa. Am J Respir Cell Mol Biol 1996;15:443-450.
[43]Boyce JA. Mast cells: beyond IgE. J Allergy Clin Immunol 2003; 111:24-32.
[44]Driscoll PV, Naclerio RM, Baroody FM. CD4+ lymphocytes are increased in the sinusmucosa of children with chronic sinusitis. Arch Otolaryngol Head Neck Surg 1996;122:1071-1076.
[45]Blair C, Nelson M, Thomson K, et al. Allergic inflammation enhances bacterial sinusitis inmice. J Allergy Clin Immunol 2001; 108:424-429.
[46]Jyonouchi H, Sun S, Rimell F. Cytokine production by sinus lavage, bronchial lavage, andblood mononuclears in chronic rhinosinusitis with or without atopy. Arch Otolaryngol HeadNeck Surg 2000; 126:522-528.
[47]Riccio AM, Tosca MA, Cosentino C, et al. Cytokine pattern in allergic and non-allergicchronic rhinosinusitis in asthmatic children. Clin Exp Allergy 2002; 32:422-426.
[48]Ghamdi KA, Ghaffar O, Small P, et al. IL-4 and IL-13 expression in chronic sinusitis:relationship with cellular infiltrate and effect of topical corticosteroid treatment. JOtolaryngol 1997; 26:160-166.
[49]Wright ED, Frenkiel S, Al-Ghamdi K. Interleukin-4, interleukin-5, andgranulocyte-colony-stimulating factor receptor expression in chronic sinusitis and responseto topical steroids. Otolaryngol Head Neck Surg 1998; 118:490-495.
[50]Ferguson BJ, Johnson JT. Allergic rhinitis and rhinosinusitis: is there a connection betweenallergy and infection? Postgrad Med 1999; 105:55-58.
[51]Slavin RG, Zilliox AP, Samuels LD. Is there such an entity as allergic rhinosinusitis?[abstract]. J Allergy Clin Immunol 1988; 81:284.
[52]Braunstahl GJ, Kleinjan A, Overbeek SE, et al. Segmental bronchial provocation inducesnasal inflammation in allergic rhinitis patients. Am J Respir Crit Care Med 2000;161:2051-2057.
[53]Braunstahl GJ, Overbeek SE, Fokkens WJ, et al. Segmental bronchoprovo-cation in allergicrhinitis patients affects mast cell and basophil numbers in nasal and bronchial mucosa. Am JRespir Crit Care Med 2001; 164:858- 865.
[54]Baroody FM, Saengpanich S, deTineo M, et al. Nasal allergen challenge leads to bilateralmaxillary sinus eosinophil influx [abstract]. J Allergy Clin Immunol 2002; 109:S216.
[55]Schleimer RP, Togias AG. Introduction: systemic aspects of allergic disease. J Allergy ClinImmunol 2000; 106:S191.
[56]Feger TA, Rupp NT, Kuhn FA, et al. Local and systemic eosinophil activation in allergicfungal sinusitis. Ann AllergyAsthma Immunol 1997; 79:221-225.
[57]Stewart AE, Hunsaker DH. Fungus-specific IgG and IgE in allergic fungal rhinosinusitis.Otolaryngol Head Neck Surg 2002; 127:324-332.
[58]Khan DA, Cody T, George TJ, et al. Allergic fungal rhinosinusitis: an immunohistologicanalysis. J Allergy Clin Immunol 2000; 106:1096-1101.
[59]Ponikau J, Sherris DA, Kern EB, et al. The diagnosis and incidence of allergic fungalsinusitis. Mayo Clin Proc 1999; 74:877-884.
[60]Karp MW, Santeliz J, Karp CL. The germless theory of allergic disease: revisiting thehygiene hypothesis. Nat Rev Immunol 2002, 1:69-75.
[61]Allmers H, Schmengler J, Skudlik C. Primary prevention of natural rubber latex allergy inthe German health care system through education and intervention. J Allergy Clin Immunol2002; 88:16-22.
[62]Terreehorst I, Hak E, Oosting AJ, et al. Evaluation of impermeable covers for bedding inpatients with allergic rhinitis. N Engl J Med 2003; 349:237-246.
[63]Naclerio RM, Kagey-Sobotka A, Lichtenstein LM. Terfenadine, an H1 antihistamine,inhibits histamine release in vivo in the human. Am Rev Respir Dis 1990; 142:167-171.
[64]Walsh GM. The clinical relevance of the anti-inflammatory properties of antihistamines.Allergy 2000; 55:53-61.
[65]Braun JJ, Alabert JP, Michel FB, et al. Adjunct effect of loratadine in the treatment of acutesinusitis in patients with allergic rhinitis. Allergy 1997; 52:650-655.
[66]Borish L. The role of leukotrienes in upper and lower airway inflammation and theimplications for treatment. Ann AllergyAsthma Immunol 1996; 105:222- 225.
[67]Steinke JW, Bradley D, Arango P, et al. Cysteinyl leukotriene expression in chronichyperplastic sinusitis-nasal polyposis: importance to eosinophilia and asthma. J Allergy ClinImmunol 2003; 111:342-349.
[68]Bascom R, Wachs M, Naclerio RM, et al. Basophil influx occurs after nasal antigenchallenge: effects of topical corticosteroid pretreatment. J Allergy Clin Immunol 1988;81:580-589.
[69]Pipkorn U, Proud D, Lichtenstein LL, et al. Inhibition of mediator release in allergic rhinitisby pretreatment with topical glucocorticoids. N Engl J Med 1987; 316:1506-1510.
[70]Siegel SC, Katz R, Rachelefsky G, et al. Multicenter study of beclometha-sone dipropriate inadults with seasonal allergic rhinitis. J Allergy Clin Immunol 1982; 69:345-353.
[71]Johansen LV, Illum P, Kristensen S, et al. The effect of budesonide (Rhinocort) in thetreatment of small and medium-sized nasal polyps. Clin Otolaryngol 1993; 18:524-527.
[72]Ruhno J, Andersson B, Denberg J, et al. A double-blind comparison of intranasal budesonidewith placebo for nasal polyps. J Allergy Clin Immunol 1990; 86:946-953.
[73]Lildholt T, Rundcrantz H, Lindquist N. Efficacy of topical corticosteroid powder for nasalpolyps: a double-blind, placebo-controlled study of budesonide. Clin Otolaryngol 1995;20:26-30.
[74]Berggren F, Johansson L. Cost effectiveness of nasal budesonide versus surgical treatmentfor nasal polyps. Pharmacoeconomics 2003; 21:351-356.
[75]Barlan IB, Erkan E, Bakir M, et al. Intranasal budesonide spray as an adjunct to oralantibiotic therapy for acute sinusitis in children. Ann Allergy Asthma Immunol 1997;78:598-601.
[76]Dolor TJ, Witsell DV, Helkamp AS, et al. Comparison of cefuroxime with or withoutintranasal fluticasone for the treatment of rhinosinusitis. JAMA2001; 286:3097-3105.
[77]Meltzer EO, Orgel AH, Backhaus JW, et al. Intranasal flunisolide spray as an adjunct to oralantibiotic therapy for sinusitis. J Allergy Clin Immunol 1993; 92:812-823.
[78]Meltzer EO. Efficacy and patient satisfaction with cromolyn sodium nasal solution in thetreatment of seasonal allergic rhinitis: a placebo-controlled study. Clinical therapeutics 2002;24:942-952.
[79]Birchall MA, Henderson JC, Studham JM, et al. The effect of topical sodium cromoglycateon intranasal histamine challenge in allergic rhinitis. Clin Otolaryngol 1994; 19:521-525.
[80]Melen I, Friberg B, Andreasson L, et al. Effects of phenylpropanolamine on ostial and nasalpatency in patients treated for chronic maxillary sinusitis. Acta Otolaryngol 1986;101:494-500.
[81]Melen I, Andreasson L, Invarsson A, et al. Effects of phenylpropanolamine on ostial andnasal airway resistance in healthy individuals. Acta Otolaryngol 1986; 102:99-105.
[82]Bende M, Loth S. Vascular effects of topical oxymetazoline on human nasal mucosa. JLaryngol Otol 1986; 100:285-288.
[83]Wawrose SF, Tami TA, Amoils CP. The role of guaifenesin in the treatment of sinonasaldisease in patients infected with human immunodeficiency virus (HIV). Laryngoscope 1992;102:1225-1228.
[84]Durham SR, Walker SM, Samantha M, et al. Long-term clinical efficacy of grass-pollenimmunotherapy. N Engl J Med 1999; 341:468-475.
[85]Nishioka GJ, Cook PR, Davis WE, McKinsey JP. Immunotherapy in patients undergoingfunctional endoscopic sinus surgery. Otolaryngol Head Neck Surg 1994; 110:406-412.
[86]Mabry RL, Marple BF, Folker RJ, Mabry CS. Immunotherapy for allergic fungal sinusitis:three years' experience. Otolaryngol Head Neck Surg 1998; 119:648-651.
[87]Jiang RS, Hsu CY. Functional endoscopic sinus surgery in children and adults. Ann OtolRhinol Laryngol 2000; 109:1113-1136.
[88]Senior BA, Kennedy DW, Tanabodee J, et al. Long-term results of functional endoscopicsinus surgery. Laryngoscope 1998; 108:151-157.
[89]Lavigne F, Nguyen CT, Cameron L, et al. Prognosis and prediction of response to surgery inallergic patients with chronic sinusitis. J Allergy Clin Immunol 2000; 105:746-751.
[90]Palmer JN，Kennedy DW. Medical management in functional endoscopic sinus surgeryfailures. Curr Opin Otolaryngol Head Neck surg，2003，11：1，6-12.
[1] Richtsmeier W. J.,Top 10 Reasons for Endoscopic Maxillary Sinus Surgery Failure.Laryngoscope, 2001，111:1952–1956
[2] Tallon I: Axoneme structure and components. Hum Mol Genet, 2003；12 Review Issue 1，R27-R35
[3] Coste A, Girodon E, Louis S, et al., Atypical sinusitis in adults must lead to looking forcystic fibrosis and primary ciliary dyskinesia. Laryngoscope, 2004;114(5):837-843
[4]赵长青，李泽卿主译鼻窦疾病的诊断和治疗中国医药科技出版社，2006，P30-56，235-244
[5]赵长青.鼻内镜微创手术亟待规范.临床耳鼻咽喉头颈外科杂志，2007；21（5）：193-194
[6]周兵，韩德民，崔顺九，等.鼻内镜下鼻腔外侧壁切开上颌窦手术.中华耳鼻咽喉头颈外科杂志，2007；42（10）：743-748
[7] Tanna N, Edwards JD, Aghdam H, et al. Transnasal endoscopic medial maxillectomy as theinitial oncologic approach to sinonasal nesplasms-the anatomic basis.Arch Otolaryngol HeadNeck Surg. 2007;133(11):1139-1142
[8]于洪猛，赵长青主译.额窦，上海科技教育出版社，2007；P191-199